Hyperbranched dextrins for topical use to prevent or treat at least one skin inflammation symptom
By using hyperbranched hydrogenation dextrin in the skin and mucosa, the problem of difficulty in effectively preventing or treating skin and mucosa inflammation in the prior art is solved, and the reduction of inflammatory biomarkers and maintenance of skin barrier function is achieved, which significantly reduces the Redness and moisture loss demonstrate their effectiveness in prevention and treatment.
Patent Information
- Application Number
- CN202380031776.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively prevent or treat inflammatory symptoms of the skin and mucous membranes, such as redness, fever, swelling and pain, especially irritating effects caused by cosmetics, dermatological compositions or other irritating ingredients.
Hyperbranched hydrogenation dextrin is demonstrated in a two-dimensional reconstruction human epidermal model to reduce the expression of inflammatory biomarkers such as IL-1α, IL-1β, RANTES and VEGF, and to maintain skin barrier function, thereby mitigating or Eliminate these symptoms.
Hyperbranched hydrogenation dextrin significantly reduces the expression of inflammatory markers, reduces the irritation response of the skin, significantly reduces transepiderial moisture loss, and significantly reduces redness induced by irritant substances in a short period of time, maintaining skin hydration , demonstrate its effectiveness in preventing and treating skin and mucosal inflammation.
Smart Images

Figure BDA0005066656330000341 
Figure BDA0005066656330000351 
Figure BDA0005066656330000371
Abstract
Description
Technical Field
[0001] The present invention relates to hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for topical use to prevent or treat at least one symptom selected from redness, heat, swelling and pain, and to prevent or treat symptoms of skin inflammation and mucosal inflammation. The present invention also relates to the use of these hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for preventing, reducing or eliminating irritation induced by ingredients contained in cosmetic compositions, dermatological compositions or other compositions. Prior art
[0002] The skin is both a living anatomical barrier and an exchange zone between the body and its environment, and its effectiveness determines the maintenance of a good homeostatic balance. The skin consists of a superficial layer, composed of the epidermis, and deeper layers forming the dermis and subcutaneous tissue. Each of these layers has specific properties that allow the skin to respond to and adapt to the conditions of its environment.
[0003] The mucous membranes forming the purpose of this application are membranes lining the body cavities selected from the oral cavity and the genitals. The lining is a stack of cells called epithelium. This epithelium contains specific cells that produce mucus, hence the name. Mucus lubricates and protects the organs lined with mucus. Mucous membranes play a protective role and are connected to the skin. Therefore, inflammation of the mucous membranes, mucous membrane folds or mucous membrane lesions can sometimes be observed.
[0004] The skin and mucous membranes, as protective barriers of the body, are exposed to a wide range of insults, which may cause discomfort or, even in the case of very strong or more severe reactions, inflammation of the skin or mucous membranes.
[0005] Skin inflammation may notably be induced by skin irritation, which occurs when the skin comes into contact with an irritant, such as a chemical substance, such as a detergent, or such as a mechanical action, such as shaving, scrubbing, peeling or depilating. Skin irritation may also be caused by the effects of temperature, weather, ultraviolet radiation or even air pollution.
[0006] Irritation of mucous membranes (e.g., buccal mucosa) may also be induced by certain foods or drinks, leading to the formation of, for example, canker sores, or by friction, such as brushing the teeth with a toothbrush. Genital mucosa may also be irritated locally after repeated friction, use of too aggressive soaps, excessive masturbation, very frequent sexual intercourse on slightly dry mucosa, or an imbalance of the bacterial flora.
[0007] These irritants cause irritation of the skin or mucous membranes, which activates the innate immune response, the first stage of which is inflammation of the irritated tissue or mucous membrane. Inflammation of the skin or mucous membranes may also be caused by lesions involving inflammatory processes.
[0008] The effect of irritating chemicals depends on their ability to penetrate the upper layer of the skin, the stratum corneum, which acts as a protective barrier. In the case of mucous membranes, penetration of irritating chemicals is much easier because mucous membranes do not have a physical barrier constituted by keratinocytes, but are simply composed of non-keratinized epithelial cells into which substances can easily penetrate. Once the skin barrier is damaged, or once the irritant penetrates the mucous membrane, the irritant comes into contact with living cells and interacts with endogenous substances naturally present therein, thereby destroying the biological functions of skin or mucous membrane cells, or even causing tissue damage. The first biological response is an acute inflammatory reaction in damaged tissue cells. This reflects the defense of cells against invasive products in order to accelerate their elimination based on the innate immune response.
[0009] Irritants cause reversible skin damage. By applying irritants directly to the epidermal surface, their irritation potential can be assessed by various parameters such as the expression levels of key biomarkers that play a role in skin inflammation.
[0010] The inflammatory phenomenon consists of four symptoms: pain, heat, redness and swelling of tissues. Its intensity is proportional to the degree of stimulation (dose-dependent response) and the amount of cytokines produced by epidermal keratinocytes that induce and control the early inflammatory response. The cytokines that play a major role in the inflammatory cell response are the interleukins IL-1α, IL-6 and IL-8, and tumor necrosis factor α (TNF-α). IL-1β, IL-8, RANTES and VEGF are also biomarkers of inflammation.
[0011] There is a continuing need for new agents of natural or botanical origin that are capable of preventing or effectively treating symptoms selected from redness, heat, pain and swelling and of preventing or effectively treating inflammation of the skin or mucous membranes.
[0012] Furthermore, compounds known to irritate the skin, such as oxidative products (e.g. for hair dyeing), abrasive products (such as synthetic microplastics), mineral powders or pigments in cosmetic creams, surfactants and solvents used in washing or cleaning compositions, acids used for peeling (such as salicylic acid), compositions for exfoliation or cell renewal, or retinoids used in anti-aging compositions, are usually used in low doses. However, even small amounts of these compounds may cause irritation to sensitive skin.
[0013] Therefore, there is also a need to identify compounds that can prevent, reduce or eliminate the irritating effects of ingredients, particularly ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use. Summary of the invention
[0014] The applicant has demonstrated, using a two-dimensionally reconstructed human epidermis model, that the hyperbranched hydrogenated dextrins according to the invention induce a reduction in four biomarkers involved in inflammation (IL-1α, IL-1β, RANTES and VEGF).
[0015] The inflammatory markers IL-1α and IL-8 were measured 6 hours after inflammation was induced with a 0.5% aqueous solution of sodium lauryl sulfate (SLS). The results showed that the action curve of hyperbranched hydrogenated dextrin was similar to that of 0.05% aqueous solution of betamethasone, which was a reference positive control for anti-inflammatory effects.
[0016] Following these results, further studies revealed additional biomarkers of inflammation that were also affected by the treatment administered.
[0017] In this follow-up study, the IL-1α assay confirmed the results obtained previously. In fact, the overexpression of IL-1α during treatment with SLS was compensated by treatment with hyperbranched hydrogenated dextrins, bringing it back below the threshold of interleukin overexpression. A decrease in the expression of RANTES and VEGF was also observed with treatment with hyperbranched hydrogenated dextrins after SLS inflammation. In addition, IL-1β was also shown to be underexpressed in the presence of hyperbranched hydrogenated dextrin treatment.
[0018] Thus, it was found that, for these 4 biomarkers involved in inflammatory mechanisms, treatment with hyperbranched hydrogenated dextrins induced a decrease in these signals.
[0019] The applicant has also demonstrated that the hyperbranched dextrins according to the invention are as effective as betamethasone in maintaining the integrity of reconstructed human epidermal cell membranes.
[0020] Applicants have also demonstrated that application of an aftershave lotion comprising a hyperbranched hydrogenated dextrin according to the invention reduces intracellular water loss compared to a placebo lotion.
[0021] Finally, the applicant has demonstrated that the dextrin according to the invention significantly reduces SLS-induced redness as early as 10 minutes compared to the placebo and reference groups, and that this reduction is maintained for up to 7 days thereafter. It has also been demonstrated that the dextrin according to the invention significantly reduces transepidermal water loss as early as 30 minutes after application, and then the water loss reduction value gradually increases during the treatment period of 2 to 7 days, reaching about 6.6 units greater than the placebo group (i.e., a difference of about 195%). Therefore, the dextrin according to the invention helps maintain skin hydration by maintaining the barrier function of the skin.
[0022] Therefore, the present invention relates to hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for topical use in preventing or treating at least one symptom selected from redness, heat, swelling and pain.
[0023] The invention also relates to the use of hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for preventing, reducing or eliminating the irritating effects of ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use, such as detergents. DETAILED DESCRIPTION
[0024] Hyperbranched dextrin
[0025] In a first embodiment, the dextrins for therapeutic use forming the object of the present application are hyperbranched dextrins.
[0026] By "dextrins", the Applicant means the glucose polymers obtained from granular starch by thermal conversion by the action of acids, usually in a generally dry environment, in other words on a granular material in the form of dry solid particles containing residual moisture imposed by the physical equilibrium conditions at a given temperature and pressure. Thus, maltodextrins and pyrolyzed dextrins, when modified to be hyperbranched, belong to the general family of dextrins that can be used in the present invention.
[0027] In the context of the present invention, by "dextrins", the applicant also means glucose polymers derived from the acid or enzymatic liquefaction or hydrolysis of starch, which polymers, when further chemically or enzymatically modified, in particular by branching enzymes, to provide glycosidic bonds between the anhydroglucose molecules, are often referred to as "maltodextrins", "starch hydrolysates" or "glucose syrups", whose properties differ significantly from those of the starch from which they are derived. Thus, maltodextrins, starch hydrolysates, glucose syrups and thermolyzed dextrins belong to the general family of dextrins that can be used in the present invention, as they differ from the starch from which they are derived in terms of glycosidic bonds by containing "atypical" bonds.
[0028] By "hyperbranched dextrins", the applicant means "dextrins" having glycosidic bonds between anhydroglucose molecules, the nature and amount of these glycosidic bonds being significantly different from those naturally constituting the starch from which the hyperbranched dextrins are derived. Hyperbranched dextrins have naturally occurring glycosidic bonds between anhydroglucose molecules, namely 1,6 bonds, but in greater amounts, and also have glycosidic bonds that do not naturally occur in starch, called "atypical" bonds, namely 1,3 bonds and 1,2 bonds. Hyperbranched dextrins are therefore dextrins that contain a large proportion of branched glycosidic bonds relative to the total glycosidic bonds present in the dextrin. The term "hyperbranched" may also be replaced by the term "highly branched".
[0029] "Major proportion" should be understood to mean that the proportion of branched glycosidic bonds is greater than or equal to 5% of the sum of branched glycosidic bonds and linear glycosidic bonds, preferably greater than or equal to 10%, more preferably greater than or equal to 20%, more preferably greater than or equal to 30%, more preferably greater than or equal to 40%, more preferably greater than or equal to 50%. Branched glycosidic bonds are bonds that produce a higher proportion of non-linear chains than is normal in native starch. Glycosidic bonds that produce non-linear chains are 1,6, 1,3 and 1,2 glycosidic bonds, such as Figure 1 As shown Figure 1 ]. 1,3 bonds and 1,2 bonds are atypical glycosidic bonds. The normal values of these bonds in natural starch are as follows: 1,6 bonds are about 5%, 1,2 bonds and 1,3 bonds are about 0%. The complement consists of 1,4 glycosidic bonds, which is about 95%. 1,4 bonds are the bonds that produce linear bonds.
[0030] For 1,6 glycosidic bonds, the characteristic values of the hyperbranched dextrins that can be used in the present invention are the following values: greater than 5% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably greater than or equal to 10% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, more preferably greater than or equal to 12% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, and most preferably greater than or equal to 15% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0031] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 5%, preferably at least 10%, preferably at least 12%, preferably at least 15% 1,6 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.
[0032] For 1,2 and 1,3 glycosidic bonds, the values useful in the present invention are values greater than 1% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably greater than or equal to 5% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, and more preferably greater than or equal to 10% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0033] Thus, according to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20% 1,2 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds.
[0034] According to one embodiment, the hyperbranched dextrin comprises at least 1%, preferably at least 5%, preferably at least 10%, preferably at least 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0035] For 1,4 glycosidic bonds, values useful in the present invention are values less than 90%, preferably less than 70%, preferably less than 60%, preferably less than 50% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, and preferably between 42% and 50% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0036] Thus, according to one embodiment, the branched dextrin comprises at most 90%, preferentially at most 70%, preferentially at most 50% 1,4 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0037] Preferably, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has a 1,6 glycosidic bond content of between 5% and 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15% and 20%, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0038] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention comprises, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds:
[0039] - up to 90% 1,4-glycosidic bonds,
[0040] - At least 5% 1,6 glycosidic bonds.
[0041] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention comprises, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds:
[0042] - up to 70% 1,4-glycosidic bonds,
[0043] - At least 5% 1,6 glycosidic bonds.
[0044] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:
[0045] - 5% to 40%, preferably between 10% and 30%, more preferably between 12% and 22%, and most preferably between 15% and 20% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0046] - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0047] - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0048] - 1% to 20% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
[0049] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:
[0050] - at least 5% of 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0051] Preferably at least 10%, more preferably at least 12%, and most preferably at least 15%,
[0052] - up to 70% 1,4-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-bonds, preferably up to 60% and most preferably up to 50%,
[0053] - at least 1% of 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0054] Preferably at least 5%, more preferably at least 10%, and most preferably at least 20%,
[0055] - at least 1% of 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0056] Preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.
[0057] According to one embodiment, the hyperbranched dextrin, preferably the hyperbranched hydrogenated dextrin, which can be used in the present invention has:
[0058] - 5% to 40%, preferably 10% to 30%, more preferably 12% to 22%, and most preferably 15% to 20% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0059] - 42% to 70%, preferably 42% to 60%, of 1,4 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0060] - 1% to 20%, preferably 1%, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds
[0061] to 10%, more preferably 5% to 15%, and most preferably 5% to 10% 1,3 glycosidic bonds,
[0062] - 1% to 20%, preferably 1%, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds
[0063] 5% to 10%, more preferably 5% to 15%, and most preferably 5% to 10% 1,2 glycosidic bonds.
[0064] In addition to the preparation of dextrins using the well-known thermal conversion methods applied to granular starch, in other words by using acid on granular starch, typically at elevated temperatures in a dry environment, these starch branch bond contents can also be obtained by the action of so-called "branching" or "re-branching" enzymes on liquefied starch (such as maltodextrins, starch hydrolysates or glucose syrups), wherein the liquefied starch is optionally previously or subsequently hydrogenated.
[0065] Thus, these branch bond contents can be obtained by the action of so-called "branching" or "re-branching" enzymes on liquefied starch and / or can be obtained by the action of acids on granular or liquefied starch in a drying medium, typically at elevated temperatures.
[0066] The determination of the content of 1,2, 1,3, 1,4 and 1,6 glycosidic bonds can be carried out using the classical methylation technique described in HAKOMORI, S., 1964, J. Biochem., 55, 205. "A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide". This method makes it possible to chemically characterize glycosidic bonds by distinguishing free OH groups from bonded groups. This is a destructive method that includes the steps of methylation, hydrolysis, reduction with NaBD4, acetylation and mass spectrometry analysis.
[0067] According to one embodiment, the number average molecular weight Mn of the hyperbranched dextrin is less than or equal to 10,000 g / mol, preferably less than or equal to 4500 g / mol, more preferably between 1000 g / mol and 3500 g / mol, even more preferably between 1500 g / mol and 3500 g / mol, most preferably between 1800 g / mol and 3200 g / mol.
[0068] According to one embodiment, the polynomial index of the hyperbranched dextrin, i.e. the ratio of the weight average molar mass to the number average molar mass (denoted as IP) is less than or equal to 15, preferably less than or equal to 10, more preferably less than or equal to 5, and most preferably less than or equal to 3.
[0069] Mn, Mw and IP values were measured by size exclusion chromatography based on the selective retention of solute molecules due to their penetration or non-penetration into the pores of the stationary phase. The size exclusion chromatography columns used were PSS SUPREMA 100 and PSS SUPREMA 1000, which were connected in series and coupled to a light scattering detector.
[0070] According to one embodiment, the hyperbranched dextrin has a reducing sugar content of less than or equal to 20%, preferentially less than or equal to 15%, more preferentially less than or equal to 10%, even more preferentially less than or equal to 6%, and most preferentially less than or equal to 3%, relative to the total mass of the hyperbranched dextrin. The reducing sugar content is expressed as glucose, by weight relative to the dry weight of the analyzed product, determined by the BERTRAND method.
[0071] According to one embodiment, the hyperbranched dextrins useful in the present invention have a relatively high content of residual 1,4 glycosidic bonds. The content of 1,4 glycosidic bonds is between 42% and 50% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, and the content of 1,6 glycosidic bonds is between 12% and 22% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds. In a preferred manner, the hyperbranched dextrins useful in the present invention have a 1,4:1,6 glycosidic bond ratio between 1.9 and 4.2, in particular between 2.3 and 3.5.
[0072] According to one embodiment, in the hyperbranched dextrins that can be used in the present invention, the content of 1,3 glycosidic bonds is between 1% and 10% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, and the content of 1,4 glycosidic bonds is between 42% and 50% relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds. In a preferred manner, the hyperbranched dextrins that can be used in the present invention have a 1,4:1,3 glycosidic bond ratio between 0.02 and 0.24, in particular between 0.1 and 0.2. According to one embodiment, in the hyperbranched dextrins that can be used in the present invention, the content of 1,2 glycosidic bonds is between 1% and 10%, and the content of 1,4 glycosidic bonds is between 42% and 50%. In a preferred manner, the hyperbranched dextrins that can be used in the present invention have a 1,4:1,2 glycosidic bond ratio between 0.02 and 0.24, in particular between 0.1 and 0.2.
[0073] According to one embodiment, the hyperbranched dextrins useful in the present invention have:
[0074] - 5% to 40% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0075] - a reducing sugar content less than or equal to 20% relative to the total mass of the hyperbranched dextrin,
[0076] - a polynomial index less than or equal to 15,
[0077] - and a number average molecular weight Mn less than or equal to 4500 g / mol.
[0078] According to one embodiment, the hyperbranched dextrins useful in the present invention have:
[0079] - 10% to 30% of 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0080] - 42% to 70% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0081] - a reducing sugar content less than or equal to 10% relative to the total mass of the hyperbranched dextrin,
[0082] - a polynomial index less than or equal to 10,
[0083] - and a number average molecular weight Mn between 1000 and 3500 g / mol.
[0084] According to one embodiment, the hyperbranched dextrins useful in the present invention have:
[0085] - 12% to 22% 1,6 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0086] - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0087] - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0088] - 1% to 20% of 1,2 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0089] - a reducing sugar content less than or equal to 6% relative to the total mass of the hyperbranched dextrin,
[0090] - a polynomial index less than or equal to 5,
[0091] - and a number average molecular weight Mn between 1500 and 3000 g / mol.
[0092] Hyperbranched dextrins that can be used in the present invention are commercially available, such as Production of " FM06", FM 10" and FM15S" or Tate&Lyle's " Soluble fiber” series of products.
[0093] With the name " Polydextrose" is available from Tate & Lyle or under the name "Oliggo- Other commercial products available from Cargill are hyperbranched polysaccharides or oligosaccharides which, as such or after possible hydrogenation, can be envisaged to exhibit soothing properties similar to the hyperbranched dextrins for the purposes of the present application.
[0094] Hyperbranched Hydrogenated Dextrin
[0095] In a second embodiment, the dextrins that can be used for non-therapeutic purposes for the purposes of the present application are hyperbranched hydrogenated dextrins. Such dextrins can be obtained by subjecting the hyperbranched dextrins according to the purposes of the present application to hydrogenation, or by applying a "branching" or "rebranching" process to a previously hydrogenated dextrin. Hydrogenation can be achieved, for example, by contacting an aqueous solution of the hyperbranched dextrin with hydrogen in the presence of a catalyst such as Raney nickel.
[0096] Thus, additional features may advantageously be added to the embodiments of the hyperbranched dextrins set forth above, namely, a reducing sugar content of less than or equal to 5 wt%, preferably less than or equal to 3 wt%, more preferably less than or equal to 2 wt%, more preferably less than or equal to 1 wt%, more preferably less than or equal to 0.5 wt%, and most preferably less than or equal to 0.15 wt%.
[0097] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have:
[0098] - 5% to 40% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0099] - a reducing sugar content less than or equal to 4% relative to the total mass of the hyperbranched dextrin,
[0100] - a polynomial index less than or equal to 15,
[0101] - and a number average molecular weight Mn less than or equal to 4500 g / mol.
[0102] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have:
[0103] - 10% to 30% of 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0104] - 42% to 70% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0105] - a reducing sugar content less than or equal to 3% relative to the total mass of the hyperbranched dextrin,
[0106] - a polynomial index less than or equal to 10,
[0107] - and a number average molecular weight Mn between 1000 and 3500 g / mol.
[0108] According to one embodiment, the hyperbranched hydrogenated dextrins useful in the present invention have:
[0109] - 12% to 22% 1,6 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0110] - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0111] - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds,
[0112] - 1% to 20% of 1,2 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds,
[0113] - a reducing sugar content less than or equal to 2% relative to the total mass of the hyperbranched dextrin,
[0114] - a polynomial index less than or equal to 5,
[0115] - and a number average molecular weight Mn between 1500 and 3000 g / mol.
[0116] Hyperbranched hydrogenated dextrins useful in the present invention are commercially available, such as " HM06”.
[0117] Biomarkers involved in inflammation (IL-1α, IL-1β, RANTES, and VEGF)
[0118] Inflammation is essentially an innate self-defense immune response to harmful stimuli, especially infectious agents and physical or chemical challenges. This is a temporary, coordinated and adaptive modification of cellular function in order to restore, if possible, to the pre-invasion state. The temporal expression profile of cytokines in epidermal keratinocytes is important in coordinating inflammatory responses (Kataru et al., 2009). IL-1, 6, 8 and TNF-α are known to be potent inducers of keratinocyte-derived VEGF (Detmar et al., 1995).
[0119] IL-1 is an essential proinflammatory cytokine that mediates the acute phase of inflammation by inducing local and systemic responses. IL-1α acts as an "alarm". During cell death by necrosis, IL-1α is released into the extracellular space where it stimulates chemokine production, leading to the infiltration of neutrophils and then monocytes. IL-1α is constitutively present in various epithelial cell types in healthy subjects, whereas IL-1β is mainly induced under pathological conditions.
[0120] The mediators RANTES and VEGF are growth factors for connective tissue and blood vessels.
[0121] It has been demonstrated that RANTES induces endothelial cell proliferation and migration, and participates in the formation of vascular networks via VEGF secretion. VEGF is a key mediator of skin angiogenesis and vascular permeability, which is involved in physiological processes such as wound repair and hair growth, as well as pathological conditions, including skin inflammation, skin cancer, and psoriasis. In many skin disorders closely related to angiogenesis or chronic inflammation (such as psoriasis, contact dermatitis, wound healing, and skin tumor formation), there is a significant induction of VEGF in epidermal keratinocytes, indicating that VEGF increase plays a key role in these skin problems.
[0122] RANTES chemokine is a chemoattractant for eosinophils, memory phenotype T lymphocytes and monocytes. This chemokine plays an important role in chronic inflammatory and allergic diseases.
[0123] Advantageously, it was found that, for the four biomarkers involved in inflammatory mechanisms, IL-1α, IL-1β, RANTES and VEGF, treatment with hyperbranched dextrins induced a decrease in these signals.
[0124] These results allow us to conclude that hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, are effective in preventing or treating at least one symptom selected from redness, heat, swelling and pain, and in preventing or treating skin inflammation and mucosal inflammation.
[0125] Redness, warmth, swelling, pain
[0126] The present invention relates to hyperbranched dextrin, preferably hyperbranched hydrogenated dextrin, for preventing or treating at least one symptom selected from redness, heat, swelling and pain.
[0127] Preventing at least one symptom selected from redness, heat, swelling and pain means preventing the onset of at least one of these symptoms, as well as delaying the onset of at least one of these symptoms and preventing at least one of these symptoms from getting worse.
[0128] Treating at least one symptom selected from redness, heat, swelling and pain means that at least one of these symptoms disappears, or at least the intensity of at least one of these symptoms is reduced, e.g. the intensity of redness and / or heat and / or swelling and / or pain is reduced.
[0129] Epithelial tissue
[0130] According to one embodiment, at least one symptom is localized in at least one epithelial tissue selected from keratinized multilayered squamous epithelium, non-keratinized multilayered squamous epithelium, stratified columnar epithelium, ciliated or non-ciliated pseudostratified columnar epithelium.
[0131] The epidermis is a keratinized, multilayered squamous epithelium.
[0132] The oral, vaginal, and urogenital mucosa are nonkeratinized, multilayered squamous epithelia.
[0133] The nasal cavity and conjunctival fornix are lined with stratified columnar epithelium.
[0134] The nasal mucosa is a pseudostratified columnar epithelium that may or may not be ciliated.
[0135] Thus, according to one embodiment, at least one symptom is located in the epidermis, oral cavity, vaginal mucosa, nostrils, conjunctival fornix or nasal mucosa.
[0136] According to one embodiment, at least one symptom is localized on the epidermis, preferentially on the epidermis of the skin or scalp.
[0137] According to one embodiment, the epidermis of the skin or scalp is a sensitive epidermis.
[0138] Skin inflammation
[0139] Skin inflammation is understood to mean the presence of four symptoms on the epidermis, namely redness, warmth, swelling and pain.
[0140] The epidermis is preferentially the epidermis of the skin or scalp.
[0141] According to one embodiment, the epidermis is a sensitive epidermis.
[0142] Skin inflammation is also called dermatitis.
[0143] Thus, according to one embodiment, the present invention relates to hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for topical use to prevent or treat inflammatory conditions of the skin.
[0144] For purposes of the present invention, "topical" means application to a body surface such as the skin or mucous membranes.
[0145] Preventing skin inflammation symptoms not only means preventing the onset of these four skin inflammation symptoms, but also includes delaying the onset of these four skin inflammation symptoms and preventing these four skin inflammation symptoms from worsening.
[0146] Treating skin inflammatory symptoms means that these four skin inflammatory symptoms disappear, or at least the intensity of these four skin inflammatory symptoms decreases, such as the intensity of redness, heat, swelling and pain decreases.
[0147] Non-pathological causes
[0148] There are many causes for one or all of the symptoms selected from redness, heat, swelling and pain.
[0149] Thus, at least one symptom is induced by at least one condition selected from the group consisting of an infectious agent, a chemical, an ingredient contained in a topical composition for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use (e.g. a detergent), a mechanical insult, an environmental factor, a thermal insult, food and beverages. Another non-pathological cause may be an oral or intravenous therapeutic treatment that produces one or more secondary skin reactions.
[0150] Infectious agents include bacteria, yeasts, molds, parasites, viruses, and even mites, lice and insects when they attack the skin through stings or bites. For example, dry patches caused by parasites can be cited.
[0151] Mechanical aggression includes rubbing, brushing, shaving, cutting, micro-cutting, physical aggression, hair removal, abrasion, scrubbing, frequent washing, hard water with high concentration of lime, etc.
[0152] Friction can be caused by clothing rubbing against the skin or by skin rubbing against skin. For example, woolen clothing, or underwear worn in contact with the skin (such as socks or scarves) rub against the skin and can thus cause skin irritation. Friction can also be caused by wearing a helmet for a long time, a mask (especially a surgical mask), weather protection, protection against microorganisms (such as bacteria or viruses), protection against chemicals or solvents, or protection against dust.
[0153] Abrasion refers to contacting the skin or mucous membrane with an abrasive, in other words, solid particles that are usually irregularly shaped and not smooth. For the skin, abrasives include gravel, sand, and magnesium oxide. For the oral mucosa, abrasives can include calcium carbonate.
[0154] Brushing refers to the action of a brush, especially a toothbrush, against the gums.
[0155] Environmental factors include pollution, exposure to sunlight, radiation (such as X-rays and ultraviolet rays), cold, wind, dryness, humidity, etc.
[0156] Heat stroke includes overexposure to the sun or exposure to sources of heat or cold.
[0157] Food and beverages include spices, dairy products, dried fruits, nuts, pineapples, acidic foods, vinegar, alcohol, etc.
[0158] Chemicals include irritants and pollutants such as detergents, pollution, cigarette smoke, household products, especially household cleaners.
[0159] Ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use include cosmetic active ingredients, dermatological active ingredients, surfactants, solvents, preservatives, fragrances, acids, exfoliants and detergents.
[0160] These potentially irritating active ingredients have been described in document FR 2 902 998. Examples of dermatological or cosmetic active ingredients thus include certain peeling agents, which may also be exfoliants.
[0161] Specific exfoliants include abrasive / exfoliating particles from mineral, organic, natural or synthetic sources. Of particular note are pumice particles, silica, polyethylene beads, nylon and fruit pit powders.
[0162] Among these peeling agents, the following may cause skin irritation: saturated and unsaturated monocarboxylic acids (acetic acid), saturated and unsaturated dicarboxylic acids, saturated and unsaturated tricarboxylic acids; α-hydroxy acids and β-hydroxy acids that are monocarboxylic acids; α-hydroxy acids and β-hydroxy acids that are dicarboxylic acids; α-hydroxy acids and β-hydroxy acids that are tricarboxylic acids; keto acids, α-keto acids and β-keto acids that are polycarboxylic acids, polyhydroxymonocarboxylic acids, polyhydroxydicarboxylic acids and polyhydroxytricarboxylic acids.
[0163] Of particular note among the α-hydroxy acids or their esters are glycolic acid, diacids such as octadecenedioic acid, citric acid, lactic acid, tartaric acid, malic acid or mandelic acid, their esters such as dialkyl tartrate (C12-C13), branched C12-C13 triol citrates.
[0164] Among the beta-hydroxy acids are salicylic acid and its derivatives (including n-octanoyl-5-salicylic acid).
[0165] Alpha-keto acids include ascorbic acid and its derivatives.
[0166] Other peeling agents include: pyruvic acid, gluconic acid, glucuronic acid, oxalic acid, malonic acid, succinic acid, acetic acid, gentisic acid, cinnamic acid, azelaic acid; phenol; resorcinol; urea and its derivatives, hydroxyethyl urea; fructooligosaccharides; jasmonic acid and its derivatives; ascorbic acid and its derivatives, trichloroacetic acid; Sophora flavescens extract and resveratrol.
[0167] From the perspective of peeling agents, those that are able to act on enzymes involved in desquamation or degradation of keratodesmosomes may also cause skin irritation.
[0168] These peeling agents include mineral salt chelating agents such as EDTA; N-acyl-N,N',N'-ethylenediaminetriacetic acid; aminosulfonic acid compounds, especially (N-2 hydroxyethylpiperazine-N-2-ethane)sulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (precysteine); glycine-type α-amino acid derivatives; honey; sugar derivatives such as O-octanoyl-6-D-maltose, O-linoleyl-6-D-glucose and N-acetylglucosamine.
[0169] Retinoids are also compounds that may cause skin irritation. Examples include retinol and its esters, retinal, 30 retinoic acid and its derivatives, and adapalene.
[0170] Salts and derivatives of the compounds mentioned above, such as cis or trans forms, racemic mixtures, dextrorotatory or levorotatory forms are also considered as compounds that may cause skin irritation.
[0171] Other dermatological or cosmetic active ingredients that may cause skin irritation are also listed below:
[0172] - urea and its derivatives, such as hydroxyethyl urea,
[0173] - Certain vitamins, such as vitamin D and its derivatives, such as vitamin D3, vitamin D2, calcitriol, calcipotriol, tacalcitol, 24,25-dihydroxyvitamin D3,
[0174] 1-OH vitamin D2 and 1,24-dihydroxyvitamin D2; vitamin B9 and its derivatives,
[0175] - peroxides, such as benzoyl peroxide and hydrogen peroxide,
[0176] - Hair loss inhibitors, such as minoxidil and its derivatives, such as aminexyl,
[0177] - Hair dyes and colorants, such as aminophenols and their derivatives, such as p-phenylenediamine (p-
[0178] PDA), N-phenyl p-PDA, toluene 2,5-diamine sulfate, m-phenylenediamine (m-
[0179] PDA), toluene 3,4-diamine and o-phenylenediamine (o-PDA),
[0180] - antiperspirants, such as aluminium salts, such as aluminium hydroxychloride,
[0181] - Deodorant,
[0182] - depilatory and / or hair waving active ingredients, such as thioglycolates and ammonia,
[0183] - thioglycolate and its salts, - phenoxyethanol,
[0184] -1,2-pentanediol,
[0185] -Alcoholic fragrance solutions (perfumes, eau de toilette, aftershave, deodorants)
[0186] -Anthralin (dioxanthrol),
[0187] -anthranode
[0188] -Lithium salts
[0189] - depigmenting agents (e.g. hydroquinone, high concentrations of vitamin C, kojic acid),
[0190] - Certain slimming active ingredients with a heating effect,
[0191] - nicotinic acid esters and their derivatives,
[0192] - Capsaicin, anti-lice active ingredient (pyrethrin),
[0193] - antiproliferative agents, such as 5-fluorouracil or methotrexate,
[0194] - antiviral agents,
[0195] - Antiparasitic drugs,
[0196] - antifungal agents,
[0197] - Antipruritic,
[0198] - anti-seborrheic dermatitis agents,
[0199] - certain sunscreens,
[0200] - Pro-pigmenting agents, such as psoralen and methylangeciline, and
[0201] - A mixture thereof.
[0202] Preservatives include propionic acid, calcium propionate, formaldehyde, paraformaldehyde, o-phenylphenol or its salts, zinc pyrithione, sodium sulfite, bisulfite or metabisulfite, ammonium, potassium, chlorobutanol, methyl paraben, ethyl paraben, propyl paraben, formic acid and its salts (such as sodium formate), benzoic acid and its salts (such as sodium benzoate), sorbic acid and its salts (such as calcium sorbate, sodium sorbate, potassium sorbate), salicylic acid and its salts, dehydroacetic acid and its salts (such as sodium dehydroacetate), undecylenic acid and its salts (such as calcium undecylenate), , potassium undecylenate, sodium undecylenate), phenoxyethanol, 1,2-dihydroxymethyl-5,6-dimethylhydantoin, benzyl alcohol, chlorhexidine, chlorhexidine diacetate, chlorhexidine digluconate, chlorhexidine hydrochloride, behenyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, cetrimonium bromide, lauryltrimethylammonium chloride, lauryltrimethylammonium bromide, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, hexamidine, hexamidine dihydroxyethyl sulfonate, chlorphenesin, benzalkonium chloride, benzalkonium bromide, benzalkonium saccharinate, ethyl lauroyl arginate.
[0203] Surfactants include anionic surfactants, cationic surfactants and amphoteric surfactants, more particularly anionic surfactants such as alkyl sulfates and alkyl ether sulfates, such as lauryl sulfate and lauryl ether sulfate, and their salts, especially the sodium salt.
[0204] In a preferred embodiment of the present invention, the compound that may cause skin irritation is selected from surfactants, bases and acids. The acid can be selected from citric acid, lactic acid, acetic acid, dehydroacetic acid, formic acid, gluconic acid, succinic acid, salicylic acid, glucuronic acid, retinoic acid, glycolic acid, phytic acid, ascorbic acid and levulinic acid. The base can be selected from sodium hydroxide, potassium hydroxide, triethanolamine and aminomethyl propanol.
[0205] Preferably, at least one symptom selected from redness, heat, swelling and pain is induced by chemicals, ingredients contained in cosmetic or dermatological preparations, mechanical aggression, thermal aggression or environmental factors.
[0206] More preferably, at least one symptom selected from redness, heat, swelling and skin pain or inflammation is induced by exposure to chemicals, or ingredients selected from surfactants, detergents, hair oxidizing agents or bleaching agents contained in a topical composition for cosmetic or dermatological use, or is induced by mechanical aggression selected from friction, shaving, cutting, micro-cutting, depilation, abrasion and exfoliation.
[0207] There are also many non-pathological causes of skin inflammation. In fact, skin inflammation can be induced not only by at least one of the aforementioned causes, selected from infectious agents, chemical products, ingredients contained in cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or topical compositions for household use, mechanical aggression, environmental factors, thermal aggression, food and beverages, but also by skin irritation, skin corrosion, endogenous skin inflammation or a combination of these causes.
[0208] Skin irritation includes acute skin irritation (or acute irritant contact dermatitis), cumulative skin irritation (or cumulative irritant contact dermatitis) and phototoxicity (or phototoxic dermatitis).
[0209] "Acute skin irritation" or "acute irritant contact dermatitis" is understood to mean a reversible local inflammatory response of the skin of a normal organism to a direct insult caused by a single application of a noxious substance, without the intervention of immune mechanisms.
[0210] "Cumulative skin irritation" or "cumulative irritant contact dermatitis" is understood to mean reversible irritation caused by repeated or prolonged exposure to substances that do not themselves cause acute irritation.
[0211] "Phototoxicity" or "phototoxic dermatitis" is understood to mean irritation due to light-induced molecular changes in the structure of chemicals applied to the skin.
[0212] Thus, according to one embodiment, the skin irritation is selected from cumulative irritant contact dermatitis, acute irritant contact dermatitis and phototoxic dermatitis.
[0213] In a preferred embodiment, the skin irritation is cumulative irritant contact dermatitis.
[0214] "Skin corrosion" is understood to mean a direct chemical action on normal living skin, leading to its disintegration at the point of contact and irreversible changes. Corrosion manifests itself as ulceration and necrosis, followed by scarring.
[0215] According to one embodiment, the phototoxicity is induced by chemicals, cosmetics or ingredients contained in topical compositions for dermatological use.
[0216] In a preferred embodiment, the skin inflammation is induced by exposure to chemicals, ingredients contained in cosmetic or topical compositions for dermatological use, as well as mechanical and thermal insults.
[0217] In a preferred embodiment, the skin inflammation is induced by exposure to chemicals, cosmetics or ingredients contained in topical compositions for dermatological use, preferably by ingredients contained in topical compositions for cosmetic or dermatological use.
[0218] "Endogenous skin inflammation" is understood to mean inflammation induced by one or more biological factors within the human organism or by one or more pathogens endogenous to the human organism, in other words, inflammation induced by pathogens synthesized by the human organism itself.
[0219] Causes of mucosal inflammation
[0220] According to one embodiment, the present invention relates to hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for use in preventing or treating mucosal inflammatory conditions.
[0221] According to one embodiment, the inflammation is selected from oral mucosal inflammation, preferentially oral mucosal inflammation caused by anionic surfactants, or oral mucosal inflammation caused by irritation caused by brushing. The anionic surfactant can be applied to the oral mucosa with the aid of toothpaste (usually accompanied by brushing) or mouthwash (usually not accompanied by brushing).
[0222] Thus, according to one embodiment, the mucosal inflammation is induced by ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use, such as surfactants, or by mechanical aggression, such as brushing.
[0223] Pathological causes
[0224] According to one embodiment, the skin inflammation is induced by a skin lesion involving an inflammatory process.
[0225] According to one embodiment, the skin lesions involving inflammatory processes are selected from psoriasis, skin atopy, atopic dermatitis, allergic reactions of the immediate hypersensitivity type, allergic reactions of the delayed hypersensitivity type, inflammatory hyperpigmentation, immune skin diseases, actinic elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis and autoimmune white hair disease, erythema,
[0226] Immediate hypersensitivity allergic skin reactions include urticaria, solar dermatitis (or sun allergy), and allergic reactions due to exposure to surfactants.
[0227] Delayed hypersensitivity allergic skin reactions include contact dermatitis, seborrheic dermatitis, acne, and eczema.
[0228] Erythema can be caused by ultraviolet rays, friction, or micro-cuts.
[0229] According to one embodiment, the atopic dermatitis is atopic dermatitis of sensitive skin.
[0230] Preferentially, the skin lesion is selected from erythema, psoriasis, skin atopy, atopic dermatitis, immediate hypersensitivity type allergic reaction, delayed hypersensitivity type allergic reaction and inflammatory hyperpigmentation.
[0231] Preferentially, erythema is caused by ultraviolet light.
[0232] Preferentially, the immediate hypersensitivity type allergic reaction is urticaria.
[0233] Preferably, the delayed hypersensitivity type allergic reaction is selected from contact dermatitis and eczema.
[0234] According to one embodiment, the mucosal inflammation is induced by a skin lesion involving an inflammatory process.
[0235] According to one embodiment, the skin lesions are selected from lesions of the oral mucosa, vaginal mucosa and urogenital mucosa, preferentially from lesions of the oral mucosa.
[0236] According to one embodiment, the oral mucosal lesion is selected from gingivitis, oral lichen planus, oral ulcers, etc.
[0237] The terms "prevention" or "treatment" or "prevention method" or "treatment method" are not absolute terms, but refer to a designed procedure or plan of action, even if the probability of success is low, which is used to induce an overall beneficial effect, such as disappearance of lesions, but also to induce a delay in the onset of symptoms of lesions, or a reduction in the severity of one or more symptoms. Typically, in the case of skin inflammation induced by a skin lesion involving an inflammatory process, prevention refers not only to preventing the symptoms of the lesion, but also to preventing the symptoms of the lesion from worsening.
[0238] The present invention also relates to a method for preventing or treating skin inflammatory symptoms induced by skin lesions involving inflammatory processes, comprising administering hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, to a patient in need thereof.
[0239] The present invention also relates to the use of hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, for obtaining a medicament for preventing or treating skin inflammatory symptoms induced by skin lesions involving inflammatory processes.
[0240] The present invention also relates to a composition comprising hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, which has therapeutic use in preventing or treating skin inflammatory symptoms induced by skin lesions involving inflammatory processes.
[0241] Prevention and / or mitigation of chemical, or cosmetic, dermo-cosmetic, dermatological, pharmaceutical, medical, veterinary or household Irritating effects of ingredients contained in topical compositions of use
[0242] According to one embodiment, the present invention relates to the use of hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, for preventing, reducing or eliminating the irritating effects of chemical products in contact with the skin and mucous membranes, or of topically applied ingredients contained in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use.
[0243] Irritation refers to the occurrence of at least one symptom selected from redness, heat, swelling and pain in epithelial tissue or mucous membranes after exposure of the skin or mucous membranes to one or more chemicals, or after topical application of a cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household composition containing ingredients that irritate epithelial tissue or mucous membranes.
[0244] Hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, can be applied before or after the use of these ingredients or active ingredients with irritating effects in order to prevent, greatly reduce or even eliminate such irritating effects. In both cases, the hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, will be included in topical preparations for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical or veterinary use, which will practically contain no ingredients or active ingredients with irritating effects.
[0245] The presence of hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, in topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use, preferably in topical compositions for cosmetic, dermocosmetic or dermatological use, which contain one or more ingredients or active ingredients with an irritating effect, also makes it possible to significantly reduce or even eliminate this irritating effect. This also makes it possible to increase the amount of products with irritating side effects compared to the amount of products usually used, in order to improve the efficacy. This also makes it possible to apply products with an irritating effect to sensitive skin.
[0246] Topical compositions for cosmetic, dermocosmetic, dermatological, pharmaceutical, medical, veterinary or household use may contain one or more ingredients or active ingredients that may cause skin irritation, such as cosmetic or dermatological active ingredients, surfactants, solvents, preservatives, fragrances and detergents.
[0247] These potentially irritating ingredients or active ingredients are as previously described.
[0248] Dermatological compositions or dermatologically acceptable compositions
[0249] Hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, can be incorporated into dermatological compositions, or more generally into any composition made of a dermatologically acceptable medium, and then brought into contact with an epithelial tissue selected from keratinized multilayered squamous epithelium, non-keratinized multilayered squamous epithelium, stratified columnar epithelium, pseudostratified columnar epithelium with or without cilia, preferably with the epidermis, oral cavity, oral mucosa, vaginal mucosa, nostrils, nasal mucosa, most preferably with the skin or oral mucosa.
[0250] Therefore, the present invention also relates to a dermatological composition or a dermatologically acceptable composition comprising a hyperbranched hydrogenated dextrin and a dermatologically acceptable medium.
[0251] The term "dermatologically acceptable composition" or "dermatologically acceptable" is understood to mean any composition that has no or minimal harmful side effects, in particular does not produce unacceptable redness, heat, tightness or stinging, or more generally does not produce inflammation, for the user who brings the dermatologically acceptable composition into contact with his epithelial tissue, preferentially his skin or mucous membrane. Thus, dermatologically acceptable compositions are compatible with human epithelial tissue and human mucous membranes. Dermatologically acceptable compositions include pharmaceutical, medical and household compositions, including detergent compositions.
[0252] The composition according to the invention may also be another topical composition intended for preventive or therapeutic treatment of at least one epithelial tissue selected from keratinized multilayer squamous epithelium (epidermis), non-keratinized multilayer squamous epithelium (oral, vaginal mucosa), stratified columnar epithelium (nose, conjunctival fornix), pseudostratified columnar epithelium with or without cilia (nasal mucosa). Thus, the composition may be a topical composition for dermatological, pharmaceutical, medical or veterinary use for the care of skin and epithelial tissues.
[0253] Application form
[0254] The dermatological composition according to the invention may be in any pharmaceutical form usually used for topical application, such as an aqueous, hydroalcoholic or oily solution, a dispersion or solution of the emulsion or serum type, a milky emulsion of liquid or semi-liquid consistency (obtained by dispersing a fatty phase in an aqueous phase (O / W) or vice versa (W / O)), or a milky emulsion of soft, semi-solid or solid consistency, a creamy emulsion or suspension, an aqueous or anhydrous gel, an anhydrous composition, a microemulsion, a microcapsule, a solid composition of microparticles, or an ionic and / or non-ionic vesicular dispersion.
[0255] These compositions are prepared according to conventional methods known to those skilled in the art.
[0256] The composition can be applied before, during or after the onset of at least one symptom selected from redness, heat, swelling and pain or inflammation of the skin or mucous membrane, and the application can be repeated or resumed as needed.
[0257] The composition, when applied to the skin, may be fluid to some extent and have the appearance of a cream, emulsion or microemulsion, ointment, milk, lotion, serum, paste, foam, mask, fluid, balm, oil, gel or salve. The composition can optionally be applied to the skin in aerosol form. It can also be presented in solid form, for example in the form of a stick or patch, dry soap or cleansing bar.
[0258] The composition can be used as a skin care product, in particular for leave-on application, such as a day or night cream for facial and / or body skin, as a cleanser, as a make-up product, as a deodorant, as a shaving product, as an after-shave product, as an after-sun product, as a sunscreen product, or as a lip balm to protect the lips from the cold and / or the sun and / or the wind.
[0259] The composition according to the invention may also be a composition for scalp and hair care and may be in a pharmaceutical form for rinse-off or non-rinse-off application. Examples of these forms are shampoos, hair conditioners, hair masks, serums, mousses, balms, creams, sprays, conditioners, softeners, hair creams, as well as in the form of extracts, dye compositions, coloring shampoos, perming compositions, anti-hair loss lotions or gels, anti-parasitic shampoos or conditioners.
[0260] The amount of hyperbranched dextrin in these compositions can be varied to deliver an effective amount of hyperbranched dextrin to achieve a desired therapeutic response for a particular patient.
[0261] An "effective amount" or "therapeutically effective amount" of a compound is understood to mean a non-toxic but sufficient amount of the compound to provide the desired effect.
[0262] Generally, the amount or dosage administered depends on the activity of the hyperbranched dextrin, the route of administration, the severity of the lesion, the health status and medical history of the patient being treated, various factors such as body weight, diet, and possible combinations with other therapeutic agents. However, it is within the capabilities of those skilled in the art to determine the appropriate dosage and to start treatment at a dosage lower than that required to achieve the desired therapeutic effect, as well as to gradually increase the dosage until the desired effect is achieved.
[0263] According to one embodiment, the content of hyperbranched dextrin is in the range of 0.5 wt % to 50 wt %, preferentially 1 wt % to 25 wt %, more preferentially 1 wt % to 15 wt %, even more preferentially 2 wt % to 10 wt %, based on the total weight of the cosmetic composition, the dermatological composition or the dermatologically acceptable composition.
[0264] Preparation ingredients
[0265] According to one embodiment, the hyperbranched dextrin is administered topically.
[0266] The hyperbranched dextrins can be administered in several doses.
[0267] The dermatological composition or topical preparation according to the invention may further comprise a solvent selected according to the different ingredients and application forms.
[0268] According to one embodiment, the composition according to the invention may comprise an aqueous phase comprising water and, optionally, one or more water-miscible organic solvents.
[0269] The term "water-soluble solvent" refers to a compound that is liquid at room temperature and miscible with water (miscibility in water greater than 50% by weight at 25°C and atmospheric pressure).
[0270] The water-soluble solvents that can be used in the compositions according to the invention may be volatile.
[0271] Among the water-soluble solvents that may be used in the composition according to the invention, mention may be made of monoalcohols having 1 to 5 carbon atoms, such as ethanol and isopropanol, C3-C4 ketones and C2-C4 aldehydes, and polyols, such as glycerol or glycerol, sorbitol or isosorbide.
[0272] The cosmetic composition may contain, in addition to hydrogenated highly branched dextrin,:
[0273] - One or more wetting agents :
[0274] The wetting agent will be selected from esters of polyols and / or fatty acids and esters of polyethylene glycol.
[0275] "Polyol" is understood to mean any molecule having at least two free hydroxyl (-OH) groups in its structure. These polyols are preferably liquid at room temperature (25°C).
[0276] Typically the polyol is selected from the group consisting of maltitol, mannitol, xylitol, erythritol, sorbitol, isosorbide, glycerol, glucose, sucrose, polydextrose, hydrogenated glucose syrup, dextrin, maltodextrin, glucose syrup and mixtures thereof.
[0277] Examples include: Beautéby PO 071 (INCI: Sorbitol), Beautéby PO260 (INCI: mannitol), Beautéby PO 370 (INCI: Xylitol), Beautéby PO455 (INCI: Hydrogenated starch hydrolysate), Beautéby PO 500 (INCI: ISOSORBIDE), all of which are sold by ROQUETTE; Glycerin (INCI: GLYCERYL) sold by COOPER; Propylene glycol (INCI: PROPYLENE GLYCOL) sold by COOPER; Butylene glycol (INCI: 1,3-BUTYLENE GLYCOL).
[0278] Among the esters of fatty acids and polyethylene glycol, mention may be made of the product sold under the name Glucamate SSE-20 (INCI: PEG-20 Methyl Glucose Sesquistearate) by the company LUBRIZOL ADVANCED MATERIALS, Inc.
[0279] The composition comprises from 0.5% to 25% by weight of one or more wetting agents, preferably from 1% to 15% and even more preferably from 2% to 10% by weight of polyol relative to the total weight of the composition.
[0280] - One or more oils
[0281] For the purposes of the present invention, "oil" is understood to mean a compound which is liquid at room temperature (25° C.) and which, when introduced in an amount of at least 1% by weight into water at 25° C., does not dissolve in the water at all or dissolves in the water to an extent of less than 10% by weight, relative to the weight of the oil introduced into the water.
[0282] According to one embodiment, the oils will be chosen from volatile oils, non-volatile oils and mixtures thereof. Preferably, the oils are vegetable oils or oils of vegetable origin.
[0283] "Non-volatile oils" are understood to mean oils which remain on keratin materials for at least several hours at room temperature and atmospheric pressure and which have in particular a viscosity of less than 10 -3 Oil with a vapor pressure of mmHg (0.13Pa).
[0284] Among the non-volatile oils, mention may be made of fatty acid esters such as cetearyl isononanoate, isotridecyl isononanoate, isostearyl isostearate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, 2-octyldecyl palmitate, 2-octyldodecyl myristic acid or lactate, 2-diethylhexyl succinate, diisostearyl malate, triacetin, tricaprin, caprylic / capric triglyceride, a mixture of cococaprylate and caprylic acid. 12 to C15 alkyl benzoates, glycol esters such as butylene glycol cocoate, glyceryl triisostearate, tocopheryl acetate, higher fatty acids (such as myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid or isostearic acid), higher fatty alcohols (such as oleyl alcohol, vegetable oils such as avocado oil, camellia oil, hazelnut oil, tsubaki oil, cashew oil, argan oil, soybean oil, grape seed oil, sesame oil, corn oil, wheat germ oil, rapeseed oil, sunflower oil, cottonseed oil, jojoba oil, peanut oil, macadamia oil, sweet almond oil, olive oil), and mixtures thereof.
[0285] These non-volatile oils may also be hydrocarbon or silicone type oils, such as paraffin oil, squalane, petroleum jelly, dimethicone, and mixtures thereof.
[0286] According to one embodiment, the non-volatile oil is chosen from stearic acid, jojoba oil (INCI: Simmondsia Chinensis Seed Oil), grape seed oil (INCI: Vitis vinifera Seed Oil), macadamia oil (INCI: Macadamia ternifolia Seed Oil), refined oleic sunflower oil (Helianthus annuus Seed Oil), a mixture of caprate and coco-caprylate such as the product Miglyol Coco 810 (INCI: Coco-Caprylate / Caprate), sweet almond oil (INCI: Prunus Amygdalus Dulcis Oil), sesame oil (INCI: Sesame (Sesamumindicum) Seed Oil).
[0287] Volatile oil is intended to mean an oil that is capable of evaporating from the skin in less than one hour at room temperature and atmospheric pressure. The volatile oil may, for example, be chosen from silicone oils or short-chain fatty acid triglycerides in order to reduce greasiness.
[0288] According to one embodiment, the oil is present in a content ranging from 0.5% to 70% by weight, preferably from 1% to 60% by weight, preferably from 2% to 50% by weight, preferably from 5% to 40% by weight, preferably from 5% to 30% by weight relative to the total weight of the composition.
[0289] - one or more waxes and / or one or more pasty compounds .
[0290] "Wax" is intended to mean a fatty substance with a reversible liquid-solid state change and with a melting point greater than 25° C., generally between 30° C. and 90° C., which is liquid under the conditions of preparation of the composition and has an anisotropic crystalline structure in the solid state. The wax used according to the invention may consist of polar waxes or nonpolar waxes or a mixture of these two waxes. "Nonpolar" is understood to mean waxes, especially hydrocarbons, containing only carbon atoms, hydrogen atoms and / or phosphorus atoms.
[0291] Polar waxes can be selected from animal waxes, vegetable waxes and synthetic waxes or silicone waxes containing polar groups such as esters. Thus, carnauba wax, candelilla wax, beeswax (Cera alba), Chinese insect wax (Ericerus pela), Japan wax, lacquer wax, montan wax, C8-C20 acid and glycerol triesters, such as glyceryl tribehenate, particularly acetylated glycol stearate sold by VEVY under the trade name CETACENE, and mixtures thereof, can be mentioned. These waxes can be specifically used in oils in pre-dispersed form, as candelilla wax and jojoba oil mixtures. Preferably, these waxes are vegetable waxes or plant-derived waxes.
[0292] According to one embodiment, the wax is present in a content ranging from 0.5% to 50% by weight, preferably from 1% to 25% by weight, preferably from 5% to 10% by weight relative to the total weight of the composition.
[0293] “Pasty compounds” are understood to mean lipophilic fatty substances (such as waxes) capable of undergoing a reversible liquid-solid change and having an anisotropic crystalline structure in the solid state, but which differ from waxes in that they comprise a liquid part and a solid part at a temperature of 23° C. These pasty compounds are preferably vegetable fats or fats of vegetable origin, such as shea butter or camellia butter.
[0294] According to one embodiment, the pasty compound is present in a content ranging from 0.5% to 50% by weight, preferably from 1% to 25% by weight, preferably from 5% to 10% by weight relative to the total weight of the composition.
[0295] - One or more gelling agents
[0296] Gelling agents are understood to mean compounds which, in the presence of a solvent, produce macromolecular intermolecular bonds which are sufficiently strong to induce a three-dimensional network which immobilizes the solvent. Gelling agents are also understood to mean thickeners or rheological agents which act on the viscosity and flow properties of the aqueous or fatty phase.
[0297] The gelling agent allows in particular an increase in the viscosity of the continuous phase, for example, to adjust the viscosity of the continuous phase to a value ranging from 100 mPa.s to 20,000 mPa.s.
[0298] The gelling agent may be chosen from polymers of synthetic or plant origin, preferably from polymers of plant origin, chemically modified or not. Thus, the gelling agent may be chosen from: gums of plant origin, such as gum arabic, konjac gum, guar gum or their derivatives, gums extracted from algae, such as alginates; gums derived from microbial fermentation, such as xanthan gum, for example the product Keltrol CG (INCI: Xanthan Gum) sold by the company CP KELCO or the product Xanthan Gum FNCS-PC (INCI: Xanthan Gum) sold by the company JUNGBUNZLAUER INTERNATIONAL AG, mannans, scleroglucans or their derivatives; cellulose and its derivatives, such as carboxymethylcellulose or hydroxyethylcellulose; starch and its derivatives, such as modified starches, in particular pregelatinized starches, acetylated starches, hydroxypropylated starches, carboxymethylated starches, cationic starches, octenyl succinate starches, pullulan, optionally modified several times; synthetic polymers, such as polyacrylic acid or carbomers and mixtures thereof.
[0299] Among starches and starch-based blends, Beautéby ST 118 (INCI: carboxymethyl starch), Beautéby ST 720 (INCI: Hydroxypropyl Starch) and Beautéby DS112 (INCI: starch acetate (and) hydroxyethylcellulose (and) xanthan gum), both sold by Roquette.
[0300] Among the carbomers, mention will be made for example of the products Carbopol Ultrez 30 (INCI: Carbomer) or CARBOPOL ETD 2050 polymer (INCI: Carbomer) from the company LUBRIZOL ADVANCED MATERIALS, Inc.
[0301] Mention may also be made of mixtures of gum arabic and xanthan gum, such as the product Solagum AX (INCI: GUM ARABIC (AND) XANTHAN GUM) sold by the company SEPPIC, mixtures of starch and cellulose derivatives, such as the product Beautéby sold by the company ROQUETTE. DS112 (INCI: starch acetate (and) hydroxyethylcellulose (and) xanthan gum).
[0302] The gelling agent may be a mineral gelling agent selected from magnesium silicate and / or aluminum silicate. Examples of such mineral gelling agents are Pure, which is magnesium aluminum silicate.
[0303] According to one embodiment, the gelling agent is present in a content ranging from 0.1% to 50% by weight, preferably from 0.5% to 25% by weight, preferably from 0.3% to 15% by weight relative to the total weight of the composition.
[0304] - One or more binders
[0305] The term "binder" means a compound that imparts increased cohesion to the cosmetic composition. This cohesion can be adjusted depending on the amount and chemical affinity of the binder relative to the ingredients of the cosmetic composition.
[0306] Typically, the binder will be chosen from caprylic / capric triglycerides, such as the product Labrafac CC (INCI: capric / caprylic triglyceride) or cetyl dimethicone (INCI).
[0307] The binder is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 5% to 12% by weight, relative to the total weight of the composition.
[0308] - One or more emulsifiers
[0309] The cosmetic composition according to the invention may also comprise one or more oil-in-water (O / W) or water-in-oil (W / O) emulsifiers.
[0310] Oil-in-water (O / W) emulsifiers are emulsifiers with an HLB greater than or equal to 8, selected from sorbitan esters (which may be polyethoxylated), glycerol fatty acid esters, sucrose fatty acid esters or polyesters, polyethylene glycol fatty acid esters, polyether-modified polysiloxanes, polyethylene glycol fatty alcohol ethers, alkyl polyglycosides and hydrogenated lecithin, fatty acids, sorbitan esters (this list is non-limiting), and mixtures thereof.
[0311] Examples include: Montanov 68 (INCI: Cetearyl Alcohol (and) Cetearyl Glucoside) sold by SEPPIC; Montanov L (INCI: C14-C22 Alcohols and C12-C20 Alkyl Glucoside) sold by SEPPIC; Montanov 202 (INCI: Eicosanol (and) Behenyl Alcohol (and) Arachidyl Glucoside), Citrol GMS 40 (INCI: Glyceryl Stearate) sold by CRODA; or Imwitor 960K (INCI: Glyceryl Stearate) sold by BIESTERFELD; the product Imwitor 372P (INCI: Glyceryl Stearate Citrate) sold by BIESTERFELD; the product Glucate sold by LUBRIZOLADVANCED MATERIALS, Inc. SS (INCI: Methyl Glucose Sesquistearate); Polystearate (Polyglyceryl-6 Distearate) marketed by CRODA, Natragem E145 (INCI: Polyglyceryl-4 Laurate / Succinate (and) Water); Span 60 (INCI: Sorbitan Stearate) marketed by SIGMA ALDRICH.
[0312] Among the sorbitan esters, mention will be made, for example, of the product Span 20.
[0313] Among the fatty alcohols, mention will be made for example of the alcohols sold under the name Promulgen D (INCI: Cetearyl Alcohol (and) Ceteareth-20).
[0314] The O / W emulsifier may advantageously be chosen from an emulsifier system consisting of cyclodextrins and water-in-oil emulsifiers of natural origin, such as the emulsifiers sold under the name Beautéby DS146 sold by the applicant, or from emulsifier systems based on modified starch and vegetable-based gums, such as Beautéby DS421.
[0315] Water-in-oil (W / O) emulsifiers are emulsifiers with an HLB of less than 8, selected from non-ethoxylated polyol fatty acid esters, especially selected from non-ethoxylated fatty acid esters of glycerol, non-ethoxylated fatty acid esters of polyglycerol, non-ethoxylated fatty acid esters of sorbitol, non-ethoxylated fatty acid esters of anhydrohexitol, such as in particular isosorbide, mannitol, xylitol, erythritol, maltitol, sucrose, glucose, polydextrose, hydrogenated glucose syrup, dextrin and hydrolyzed starch.
[0316] The emulsifier is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 2% to 12% by weight relative to the total weight of the composition.
[0317] One or more surfactants
[0318] According to one embodiment, the composition according to the invention comprises at least one surfactant selected from ionic surfactants, nonionic surfactants, anionic surfactants, cationic surfactants or amphoteric or zwitterionic surfactants. These surfactants are selected for their detergent and foaming functions.
[0319] In another embodiment, the composition according to the invention comprises at least one surfactant chosen from anionic surfactants, amphoteric surfactants or zwitterionic surfactants.
[0320] The anionic surfactant is selected from carboxyl anionic surfactants, sulfate anionic surfactants, sulfonate surfactants, phosphate anionic surfactants and mixtures thereof, preferably sulfonate anionic surfactants, carboxyl anionic surfactants and mixtures thereof.
[0321] "Anionic surfactant" is intended to mean a surfactant that contains only anionic groups as ions or ionizable groups. In this specification, under the conditions (e.g., medium, pH) under which the composition of the invention is used, an entity is described as "anionic" when it has at least one permanent negative charge, or when it can be ionized into a negatively charged entity, and does not contain any cationic charge. "Sulfate-type anionic surfactant" is intended to mean a surfactant that contains at least one sulfate functional group (-OSO3H or -OSO3 - ) and may optionally further comprise one or more other functional groups derived from an acid, such as a carboxylic acid or carboxylate functional group (-COOH or -COO - ), sulfonate functional group (-SO3H or -SO3 - ) and / or phosphate functional groups. For example, alkyl sulfates, alkyl ether sulfates, alkyl amido ether sulfates, alkyl aryl polyether sulfates, monoglyceride sulfates and salts of these compounds are sulfate anionic surfactants. The alkyl groups of these compounds cited by way of example contain 6 to 30 carbon atoms, and the aryl represents a phenyl or benzyl group. These compounds cited by way of example can be polyoxyalkylene, in particular polyoxyethylene, and contain 1 to 50 ethylene oxide units. "Non-sulfate anionic surfactants" are intended to mean surfactants that do not fall within the definition of "sulfate anionic surfactants" as defined above.
[0322] According to the present invention, it is also intended to:
[0323] -Carboxyl anionic surfactants contain at least one carboxylic acid or carboxylate functional group (-
[0324] COOH or -COO - ), but does not contain a sulfonic acid or sulfonate functional group (-SO3H or -
[0325] SO3 - ), nor does it contain sulfate functional groups (-OSO3H or -OSO3 - );
[0326] -Sulfonate anionic surfactants contain at least one sulfonic acid or sulfonate functional group (-
[0327] SO3H or -SO3 - ), and may optionally further comprise one or more carboxylic acid or carboxylate functional groups (-COOH or -COO - ) and / or phosphate, but does not contain sulfate functional groups (-OSO3H or -OSO3 - ).
[0328] - Phosphate anionic surfactants contain at least one phosphoric acid or phosphate functional group (-
[0329] OPO3H2 or -OPO3 2- ), but does not include carboxylic acid or carboxylate functional groups (-COOH or -
[0330] COO - ), nor does it include sulfonic acid or sulfonate functional groups (-SO3H or -SO3 - ), nor sulfate functional groups (-OSO3H or -OSO3 - ).
[0331] In other words:
[0332] - Within the meaning of the present invention, it is considered that the compound contains at least one sulfate functional group (-
[0333] OSO3H or -OSO3 - ) and at least one carboxylic acid or carboxylate functional group (-COOH or –
[0334] COO - ) and, unless otherwise specified, are sulfate type anionic surfactants;
[0335] - Within the meaning of the present invention, it is considered that the compound contains at least one sulfate functional group (-
[0336] OSO3H or -OSO3 - ) and at least one sulfonic acid or sulfonate functional group (-SO3H or -
[0337] SO3 - ) and, unless otherwise specified, are sulfate type anionic surfactants;
[0338] - within the meaning of the present invention, it is considered that the compounds contain at least one sulfonic acid or sulfonate functional group
[0339] (-SO3H or -SO3 - ) and at least one carboxylic acid or carboxylate functional group (-COOH or –
[0340] COO - ) and, unless otherwise specified, are non-sulfate sulfonate anionic surfactants; within the meaning of the present invention, consider anionic surfactants containing at least one sulfate functional group (-OSO3H or -OSO3 - ) and at least one sulfonic acid or sulfonate functional group (-SO3H or -SO3 - ) and at least one carboxylic acid or carboxylate functional group (-
[0341] COOH or –COO - ) and, unless otherwise specified, are sulfate type anionic surfactants.
[0342] The carboxylic anionic surfactant can be selected from the following compounds: acyl glycinates, acyl lactylates, acyl sarcosinates, acyl glutamates, alkyl-D-galactoside-uronic acid, alkyl ether carboxylic acid, alkyl (aryl) ether carboxylic acid, alkyl (amido) ether carboxylic acid; and salts of these compounds. The alkyl and / or acyl groups of these compounds contain 6 to 30 carbon atoms, more preferably 8 to 28, more preferably 10 to 24, and even more preferably 12 to 22 carbon atoms. The aryl group preferably represents a phenyl or benzyl group. These compounds can be polyoxyalkylene, in particular polyoxyethylene, and then preferably contain 1 to 50 ethylene oxide units, more preferably 2 to 10 ethylene oxide units. C6-C24 alkyl monoesters and polyglycoside-polycarboxylic acids, such as C6-C24 alkyl polyglycoside citrate, C6-C24 alkyl polyglycoside tartrate, and their salts can also be used.
[0343] According to one embodiment, the carboxylic anionic surfactant is selected from:
[0344] - C6-C24, or even C12-C20 acyl glutamates, such as stearoyl glutamate, in particular sodium or disodium stearoyl glutamate, or cocoyl glutamate, in particular sodium or disodium cocoyl glutamate;
[0345] - acyl sarcosinates, in particular C6-C24, or even C12-C20 acyl sarcosinates, such as cocoyl sarcosinates (in particular sodium cocoyl sarcosinate), lauroyl sarcosinates (in particular sodium lauroyl sarcosinate), palmitoyl sarcosinates (in particular sodium palmitoyl sarcosinate);
[0346] - acyl lactylates, in particular C12-C28, or even C14-C24 acyl lactylates, such as behenyl lactylate (in particular sodium behenyl lactylate), (iso)stearoyl lactylate (in particular sodium (iso)stearoyl lactylate);
[0347] - acyl glycinates, in particular C6-C24 or C12-C20 acyl glycinates, such as cocoyl glycinate, in particular sodium cocoyl glycinate;
[0348] - alkyl (C6-C30) ether carboxylic acids, in particular alkyl (C6-C24) ether carboxylic acids;
[0349] - alkyl (C6-C30) aryl ether carboxylic acids, in particular alkyl (C6-C24) aryl ether carboxylic acids;
[0350] - alkyl (C6-C30) amidoether carboxylic acids, in particular alkyl (C6-C24) amidoether carboxylic acids;
[0351] - and mixtures thereof; in particular in the form of alkali metal or alkaline earth metal salts, ammonium or amino alcohols.
[0352] The anionic sulfonate surfactants may be chosen from the following compounds: alkyl sulfonates, alkylamide sulfonates, alkylaryl sulfonates, C6-C24 alkyl polyglycoside sulfosuccinates, α-olefin sulfonates, kerosene sulfonates, alkyl sulfosuccinates, alkyl ether sulfosuccinates, alkylamide sulfosuccinates, alkyl sulfoacetates, N-acyl taurates, acyl isethionates; alkyl sulfolaurates; and the salts of these compounds; the alkyl group of these compounds contains 6 to 30 carbon atoms, in particular 12 to 28, even better 14 to 24, or even 16 to 22 carbon atoms; the aryl group preferably represents phenyl or benzyl; these compounds may be polyoxyalkylened, in particular polyoxyethyleneized, in which case preferably contain 1 to 50 ethylene oxide units, better still 2 to 10 ethylene oxide units.
[0353] According to one embodiment, the anionic sulfonate surfactant is selected from: C6-C24, in particular C12-C20 alkyl sulfosuccinates, especially lauryl sulfosuccinate; C6-C24, in particular C12-C20 alkyl ether sulfosuccinates; (C6-C24) acyl isethionates, preferably (C12-C18) acyl isethionates; α-olefin sulfonates; and mixtures thereof; in particular in the form of alkali metal or alkaline earth metal, ammonium or amino alcohol salts.
[0354] According to one embodiment, the anionic surfactant can be selected from C6-C24 alkyl monoesters and polyglycoside-dicarboxylic acids, such as alkyl glucoside citrates, alkyl polyglycoside tartrates and alkyl polyglycoside sulfosuccinates, alkyl sulfosuccinamates, acyl isethionates and N-acyl taurates, all of which preferably have 12 to 20 carbon atoms in their alkyl or acyl groups. Another group of anionic surfactants that can be used in the compositions of the present invention are acyl lactylates, whose acyl groups contain 8 to 20 carbon atoms. In addition, other examples include alkyl-D-galactosiduronic acids and their salts, as well as polyoxyalkylene (C6-C24) alkyl ether carboxylic acids, polyoxyalkylene (C6-C24) alkyl (C6-C24) aryl ether carboxylic acids, polyoxyalkylene (C6-C24) alkyl amido ether carboxylic acids and their salts, in particular those having 2 to 50 ethylene oxide units, and mixtures thereof.
[0355] The phosphate anionic surfactant is selected from: C6-C24 alkyl phosphate esters, especially C12-C20 alkyl phosphate esters; C6-C24 alkyl ether phosphate esters, especially C12-C20 alkyl ether phosphate esters; and mixtures thereof.
[0356] The amphoteric or zwitterionic surfactants may be chosen from secondary, tertiary or quaternary aliphatic amine derivatives, in which the aliphatic radical is a linear or branched chain containing from 8 to 22 carbon atoms and containing at least one anionic group such as a carboxylate, sulfonate, sulfate, phosphate or phosphonate group. Mention may also be made of: (C8-C20) alkyl betaines (e.g. coco betaine), sulfobetaines, (C8-C20) alkyl sulfobetaines, (C8-C20) alkylamidoalkyl (C3-C8) betaines (e.g. cocoamidopropyl betaine); or (C8-C20) alkylamidoalkyl (C6-C8) sulfobetaines.
[0357] Cationic surfactants may be selected from cetrimonium chloride sold as Microcare Quat CTC 30 reference.
[0358] The surfactant is present in the composition according to the invention in a content ranging from 0.1% to 40% by weight, preferably from 0.5% to 30% by weight, preferably from 1% to 20% by weight, preferably from 2% to 12% by weight relative to the total weight of the composition.
[0359] - One or more film formers
[0360] The film former may be chosen from polymers of natural origin, such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) or synthetic polymers such as polyvinyl alcohol (PVA), and / or plasticizers other than polyols, such as polyethylene glycol, triethyl citrate, polysorbates, or waxes such as carnauba wax, or hydrogenated castor oil.
[0361] Another plant-derived film former is Beautéby sold by ROQUETTE ST 720 Hydroxypropylated pea starch.
[0362] The film former is present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 0.5% to 15% by weight, preferably from 1% to 12% by weight, relative to the total weight of the composition.
[0363] - One or more dyes
[0364] The cosmetic composition according to the invention may also contain at least one dye chosen from water-soluble or fat-soluble dyes, fillers having the effect of coloring and / or opacifying the composition and / or coloring keratinous substances (preferentially the skin or hair), such as pigments, perlite, lakes (water-soluble dyes adsorbed on an inert mineral carrier), and mixtures thereof. These dyes may optionally be surface-treated with a hydrophobic agent such as silanes, siloxanes, fatty acid soaps, C9-15 fluoroalcohol phosphates, acrylate / polydimethylsiloxane copolymers, C9-15 fluoroalcohol phosphate / silicon mixed copolymers, lecithin, carnauba wax, polyethylene, chitosan and optionally acylatable amino acids (such as lauroyl lysine, disodium stearoyl glutamate and aluminum acyl glutamate), phytic acid. Another natural colorant is the caramel colorant Beauté by ROQUETTE. CC 001.
[0365] "Pigment" means white or colored, mineral or organic particles intended to color and / or make a cosmetic composition opaque.
[0366] Among the pigments, mention will be made of mineral or organic, natural or synthetic pigments. Examples of pigments are especially iron, titanium or zinc oxide, and also composite pigments and magenta pigments, pearlescent pigments, interference pigments, photochromic pigments or thermochromic pigments, this list being non-limiting.
[0367] Among the pigments surface-treated with lecithin are UNIPURE WHITE LC981 HLC (INCI: CI 77891 (and) hydrogenated lecithin), UNIPURE YELLOW LC182 HLC (INCI: CI 77492 (and) hydrogenated lecithin), UNIPURE BLACK LC989 HLC (INCI: CI 77499 (and) hydrogenated lecithin), and UNIPURE RED LC381 (INCI: CI 77491 (and) hydrogenated lecithin) from SSensient Cosmetic Technologies.
[0368] Among the pigments surface-treated with phytic acid are Unipure White LC 985 PHY (INCI: CI 77891 (and) phytic acid (and) sodium hydroxide), Unipure Yellow LC 188 PHY (INCI: CI 77492 (and) phytic acid (and) sodium hydroxide), Unipure Red LC 388 PHY (INCI: CI 77491 (and) phytic acid (and) sodium hydroxide), and Unipure Black LC 998 PHY (INCI: CI 77499 (and) phytic acid (and) sodium hydroxide) from Sensient Cosmetic Technologies.
[0369] "Perlite" is intended to mean any colored or non-colored particles having a color effect by optical interference.
[0370] Among the perlites, mention will be made of titanium mica covered with metal oxides such as iron oxide or titanium oxide.
[0371] According to one embodiment, the makeup and / or skin care composition according to the invention comprises at least colored particles, preferentially pigments, such as iron oxide pigments and / or perlite.
[0372] The dye is present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 1% to 15% by weight, preferably from 0.5% to 12% by weight, relative to the total weight of the composition.
[0373] One or more fillers or sensory powders
[0374] This term is intended to mean particles of any form (especially spherical or lamellar), mineral or organic, which are insoluble in the composition. Examples of fillers or organoleptic powders are talc, boron nitride, starches such as the granular starch Beauté by ROQUETTE, ST 005 and Beautéby ST 012, polyamides, silicone resins, silicone elastomer powders and acrylic polymer powders, in particular poly(methyl methacrylate) powders or styrene acrylate copolymer powders (Sunsphere Powders sold by Dow).
[0375] The filler is present in the composition according to the invention in a content ranging from 0.5% to 20% by weight, preferably from 1% to 15% by weight, preferably from 3% to 12% by weight, relative to the total weight of the composition.
[0376] One or more sensory agents
[0377] Sensory agents can be used to modify the sensory characteristics of cosmetic or dermatological compositions, making them more pleasant to use on the skin. Sensory agents can be selected from modified starches, such as carboxymethylated starches, for example Beautéby from Roquette ST 118, silicon dioxide or talc, or mixtures thereof. These sensory agents provide a soft touch to solid compositions or a cushioning effect to liquid or gel form compositions.
[0378] The sensory agents are present in the composition according to the invention in a content ranging from 0.1% to 20% by weight, preferably from 1% to 15% by weight, preferably from 3% to 12% by weight, relative to the total weight of the composition.
[0379] - One or more active ingredients
[0380] The cosmetic composition may contain, in addition to the hyperbranched dextrin, one or more active ingredients.
[0381] These active ingredients can be of a wide range of chemical types, as the applicant has found that hyperbranched dextrins, preferentially hyperbranched hydrogenated dextrins, are fairly inert, have low reactivity and excellent compatibility with most active ingredients used in dermatological compositions / topicals. These active ingredients can be selected from moisturizers, emollients, film formers, barrier agents, stain-resistant agents, firming agents, anti-aging agents, antioxidants, exfoliants, collagen stimulators, anti-acne agents, sebum-reducing agents, blood circulation stimulators, fresheners, antibacterial agents, antifungal agents, anti-inflammatory agents, soothing agents, anti-irritants, healing agents, slimming agents, dyes, colorants, oil-shine control agents and fragrances.
[0382] Among the demulcents, preference is given to using those extracted from plants. C-glycosides (such as those described in FR2902998) are particularly suitable as demulcents.
[0383] Preferentially, the hyperbranched dextrin may be combined with another anti-inflammatory cosmetic active ingredient or a soothing active ingredient.
[0384] Active ingredients include those described in the table below:
[0385] [Table 1]
[0386]
[0387]
[0388] The active ingredient is present in the composition according to the invention in a content ranging from 0.05% to 20% by weight, preferably from 0.1% to 10% by weight, preferably from 0.5% to 6% by weight, relative to the total weight of the composition.
[0389] The dermatological compositions according to the invention are particularly suitable for intolerant skin and / or allergic skin and sensitive scalp.
[0390] Allergic skin or intolerant skin has been defined in patent FR2918886.
[0391] Intolerant skin is skin that reacts to various factors, such as the application of cosmetic or dermatological products, with sensations of warmth, tightness, stinging and / or redness. Generally speaking, these signs are associated with erythema and hyperseborrhea or acne skin, even with rosacea, with or without dry patches.
[0392] Allergic skin is skin that reacts to various factors (such as the environment, emotions, food, wind, friction, razors, hard water with a high lime content, temperature changes or wool) with pruritus, in other words itching or tingling. Most often, skin allergies are transformed into visible signs such as redness of the skin, burning of the skin or scalp, or even painful sensations.
[0393] "Sensitive scalp" is understood to mean a scalp in which sensations of itching and / or tingling and / or heating are triggered essentially by local factors such as friction, soaps, surfactants, hard water with a high lime content, shampoos or lotions. These sensations are sometimes also triggered by factors such as the environment, emotions and / or food. Scalp erythema, excessive sebum secretion and dandruff are often associated with the above signs.
[0394] Example
[0395] Example 1: In vitro determination of the effect of hyperbranched hydrogenated dextrin on skin inflammation in a 2D reconstructed human epidermis model
[0396] The aim of this study was to determine the effect of hyperbranched hydrogenated dextrin on inflammatory biomarkers using a two-dimensional (2D) human epidermal reconstruction model after inflammatory pretreatment. In this example, a hyperbranched hydrogenated dextrin sold by the applicant has been used. HM06.
[0397] Materials and methods
[0398] Reconstructed human epidermis model
[0399] The human skin equivalents reconstructed in vitro are very close to normal human skin. Since these models reproduce the barrier function characteristics of normal human skin to a large extent, they can be used to screen potential skin irritants. The model used is a two-dimensional reconstruction model of human epidermis, adapted from the method proposed by Poumay et al. in 2004 (Poumay, Y., Dupont, F., Marcoux, S., Leclerk-Smekens, M., Herin, M. And Coquette, A. (2004) A simple reconstructed human epidermis: preparation of the culture model and utilization in vitro studies. Arch. Dermatol. Res. 296: 203-211). The model includes a monolayer of normal human epidermal keratinocytes (NHEK, one of the main cell types of the skin) cultured on an inert polycarbonate insert.
[0400] Test substances can be applied topically, directly to the epidermal surface, and their irritation potential and / or efficacy can be assessed using a number of parameters, including expression levels of key cellular markers of inflammation.
[0401] Exposure of tissue to sample
[0402] The epidermis was treated with a 0.5% aqueous solution of sodium lauryl sulfate (SLS) for 6 hours to induce inflammation of the reconstructed epidermis, and then the epidermal surface was rinsed with 500 μL PBS. 20 μL of different concentrations of hydrogenated highly branched dextrin (10% and 5% ultrapure aqueous solution) and 0.05% betamethasone cream (Biogaran cream, a corticosteroid with anti-inflammatory effect) were topically applied to the epidermis at 37°C for 20 hours. During the 20 hours of rinsing with PBS, no SLS control was applied.
[0403] Under the same conditions, negative controls (UTC) followed various technical steps without the application of SLS and samples. Sodium lauryl sulfate (SLS, 0.5% aqueous solution) was used as a positive control for epidermal inflammation.
[0404] MTT cell proliferation assay
[0405] Irritating chemical compounds are able to penetrate the stratum corneum and are cytotoxic to cells in the underlying layers. Cell viability has been shown to be directly correlated with the irritation potential of these chemical compounds. Cell viability is measured by the metabolism of the vital dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, thiazolyl blue; EINECS No. 206-069-5, CAS No. 298-93-1)] by mitochondrial succinate dehydrogenase to a blue formazan salt, which is quantitatively measured after extraction from tissue.
[0406] The colored solution was measured spectrophotometrically at 570 nm using a Molecular Devices Vmax microplate reader and the absorbance values were recorded using SOFTmax PRO v4.7.1 software. Statistical analysis was performed using GraphPad Prism v5.03 software.
[0407] According to the results of this test,
[0408] - If the activity is less than 50%, the ingredient is an irritant
[0409] - If the activity is greater than 50%, the ingredient has:
[0410] - Mildly irritating, provided it activates biomarkers of inflammation;
[0411] - Non-irritating, provided that it does not activate biomarkers of inflammation.
[0412] Inflammatory markers
[0413] Interleukins IL-1α and IL-8 and tumor necrosis factor-α (TNF-α) were measured to determine whether treatment induced an inflammatory response in the treated tissues.
[0414] To this end, cell supernatants were collected after the desired treatment time and the presence of inflammatory markers was quantitatively determined using commercially available ELISA kits.
[0415] [Table 2]
[0416]
[0417] These ELISA kits are designed to quantitatively measure the markers mentioned above, particularly in culture supernatants using specific human antibodies. Samples and a series of standards are deposited in parallel into each well (96-well plate). The target marker present in the sample is bound by the antibody fixed to the bottom of the well. The wells are washed and biotinylated antibodies are added. After washing, HRP-streptavidin is deposited in the wells. The wells are washed again, TMB substrate solution is added to the wells, and the color is developed in proportion to the amount of bound markers. The color of the developer solution changes from blue to yellow, and its intensity is measured at 450nm using a Molecular Devices Vmax microplate reader. The absorbance values are recorded and analyzed using SOFTmax PRO v4.7.1 software. The inflammatory response is interpreted as a ratio of the sample to the untreated control greater than or equal to 2.
[0418] Semi-quantitative fluorescence assay of cytokines
[0419] To obtain a more complete characterization of the anti-inflammatory effects induced by hydrogenated highly branched dextrins, a panel of cytokines was measured on slides by a semi-quantitative assay. Cell culture supernatants collected after epidermal treatment were tested using the Human Cytokine Array G3 Kit (RayBiotech).
[0420] On glass slides containing antibodies of different specificities, supernatants were deposited at a rate of 100 μL per well. Then a mixture of biotin-conjugated secondary antibodies was added. Streptavidin was added and the signal intensity was detected by fluorescence. Several washes were performed after each step.
[0421] result
[0422] MTT cell proliferation assay
[0423] The samples were tested for cytotoxicity using the epidermal model and expressed as a percentage of untreated control (UTC) tissue.
[0424] [Table 3]
[0425]
[0426] *Average of 3 replicates; **SD: standard deviation
[0427] There was a significant difference in cell viability between untreated controls and treated areas, demonstrating the impact of treating inflammation with SLS.
[0428] After 20 hours, the cell viability in the presence of 0.5% SLS and Nutriose HM 06 hyperbranched dextrin was over 50%: therefore, Nutriose HM 06 hyperbranched dextrin is not an acute irritant to the epidermis. As might be expected, the same was true for samples treated with 0.5% SLS and 0.05% betamethasone. Cell viability measured in the presence of HM 06 hyperbranched dextrin was as good as that measured in the presence of 0.5% SLS and betamethasone. Since this cell viability assay confirmed that Nutriose HM 06 hyperbranched dextrin is not an acute irritant, an inflammatory marker expression assay could be performed to determine whether this dextrin could be characterized as a mild irritant, in the absence of a reduction in inflammatory marker expression, or as an anti-irritant, in the absence of a reduction in the expression of at least one major inflammatory marker.
[0429] Tests for inflammatory markers IL-1α, IL-8, and TNF-α
[0430] [Table 4]
[0431]
[0432] In the ELISA assays, the concentrations of inflammatory markers determined in duplicate from n=3 epidermis were averaged (except for IL-8, n=2). The ratio (concentration of marker in the presence of sample / concentration of marker in untreated control) was calculated for each test preparation.
[0433] A ratio greater than or equal to 2 reflects overexpression of inflammatory markers, while a ratio less than 2 indicates that inflammatory markers are not expressed.
[0434] Hyperbranched dextrin according to the present invention" HM 06" significantly reduced IL-1α expression (reduced by 25% and 28%). Betamethasone also significantly reduced IL-1α expression (reduced by 33%). Therefore, no significant difference was observed between the compound according to the present invention and betamethasone, and the positive control confirmed that the compound according to the present invention has an anti-inflammatory effect.
[0435] All concentrations of hydrogenated highly branched dextrin did not reduce the expression of interleukin IL-8 in the epidermis after inflammation, and betamethasone cream did not have any effect on the IL-8 ratio. According to the ELISA kit calibration curve, TNF-α expression was not high enough to be detected.
[0436] Tests for 4 inflammatory markers: IL-1α, IL-1β, RANTES, and VEGF
[0437] According to the results obtained by ELISA test for the inflammatory marker IL1-α, after induction of inflammation in the reconstructed epidermis with 5% SLS, the effect of 5% hyperbranched dextrin on the HM 06” effect.
[0438] [Table 5]
[0439]
[0440] The ratio (fluorescence signal intensity of the marker in the presence of the sample / fluorescence signal intensity of the marker in the untreated control) was calculated for each treatment from n=3 epidermal culture supernatants (except the untreated control, n=2).
[0441] A ratio >1.5 reflects overexpression of inflammatory markers.
[0442] A ratio <0.65 indicates insufficient expression of inflammatory markers.
[0443] According to the supplier's criteria, the signal was considered usable when it was greater than the background noise mean + 2SD. Five markers were observed to be over- or under-expressed in 0.5% SLS inflammation. The expression of these markers was also reduced after treatment with HM 06" hyperbranched dextrin.
[0444] therefore," HM 06" hyperbranched dextrin reduces:
[0445] - IL-1α expression (compared to SLS alone), which passed with values below the critical limit of 1.5
[0446] -IL-1β expression (compared to SLS alone), to less than 0.65
[0447] - IL-15 expression (compared to untreated controls) to less than 0.65
[0448] -VEGF expression (compared to SLS alone), bringing it closer to the critical threshold of 1.5
[0449] - RANTES expression (vs. SLS alone).
[0450] Thus, Nutriose HM 06 hyperbranched dextrin reduces the expression of the main inflammatory markers (IL-1α and IL-1β) and can therefore be described as an anti-irritant. The dextrin has anti-inflammatory properties.
[0451] Example 2: In vitro determination of the effect of hyperbranched dextrin on membrane integrity in a 3D reconstructed human epidermis model
[0452] The aim of this study was to assess the membrane integrity of skin cells in a three-dimensional (3D) reconstructed human epidermis model by measuring the amount of lactate dehydrogenase (LDH) in the culture supernatant using a colorimetric method. LDH is an enzyme released during cell death events. The absence of LDH secretion is a sign that epidermal cell membrane integrity is preserved.
[0453] plan
[0454] The samples of 3D reconstructed human epidermis were immersed in an aqueous solution containing 0.5 wt% sodium lauryl sulfate for 6 hours. The solution was then discarded and the samples were immersed in different solutions for 20 hours: one sample was immersed in 5 wt% sodium lauryl sulfate; One sample was immersed in 0.5 wt % aqueous solution of HM 06, another sample was immersed in 0.5 wt % aqueous solution of bisabolol, and another sample was immersed in 0.5 wt % aqueous solution of betamethasone. The amount of LDH secreted into the supernatant was then determined by colorimetry.
[0455] result
[0456] [Table 6]
[0457]
[0458] Roquette HM 06 hyperbranched dextrin is as effective as betamethasone in maintaining the integrity of reconstructed human epidermal cell membranes.
[0459] Example 2: Clinical study of shaving-induced transepidermal water loss
[0460] The aim of this study was to determine the potential of hyperbranched dextrins (based on the reference material Roquette) in a clinical study on volunteers. The effect of dextrin (sold as DMSO-HM 06) on transepidermal water loss (or TEWL) induced by shaving facial skin through topical application of said dextrin in the form of a lotion (aftershave).
[0461] Volunteers and Products
[0462] This non-invasive single-center study was conducted on 60 male volunteers aged between 30 and 55 years, with sensitive skin (based on self-report) and who routinely used mechanical razors and applied aftershave. The inclusion criteria for the volunteers are shown in the table.
[0463] [Table 7]
[0464] standard gender male Phenotype I to III age From 30 to 55 years old (divided into 3 homogeneous average age groups) Sensitive skin Yes, according to the volunteer's statement Regular razor type Mechanical razor Apply aftershave law
[0465] The volunteers were divided into three homogenous groups of 20 volunteers each, and each group received a batch of double-blade razors, a "commercial reference" shaving cream, and an aftershave lotion according to the table below.
[0466] Composition of aftershave cream
[0467] [Table 8]
[0468]
[0469] equipment
[0470] The faces of the volunteers were evaluated by measuring the transepidermal water loss (TEWL). This measurement allows the evaluation of the barrier function of the skin: the water loss value is inversely proportional to the barrier function of the skin. Using the open chamber diffusion technique, the Tewameter from Courage & Khazaka electronics The transepidermal water evaporation (expressed in g / h / m2) was measured on the shaved face surface of a person, and the average value was used.
[0471] Study Procedure
[0472] The volunteers replaced their regular razors and shaving creams with the study razors and shaving creams three days before the start of the study. The study then began with an evaluation of the volunteers' faces after shaving in the laboratory, as well as the application of aftershave lotion in the laboratory ("Day 0" measurement). This measurement was repeated 10 minutes after the "Day 0" measurement.
[0473] Between Day 0 and Day 13, volunteers performed daily shaving at home, using a new razor and the study's shaving cream and aftershave lotion for each shave. On Day 14, volunteers returned to the laboratory for facial assessments following the same protocol as Day 0, i.e., shaving followed by application of aftershave lotion, assessments were performed in the laboratory, and then a second measurement was performed 10 minutes after the first measurement.
[0474] Between days 14 and 27, the volunteers repeated the same protocol as between days 0 and 13. Then, on day 28, the volunteers returned to the laboratory for a final facial assessment using the same protocol as between days 0 and 14: that is, the assessment was performed on day 28 after shaving and application of aftershave lotion, followed by a second measurement 10 minutes after the first.
[0475] result
[0476] [Table 9]
[0477]
[0478] [Table 10]
[0479]
[0480] Thus, this study shows that application of an aftershave lotion comprising the hyperbranched hydrogenated dextrin Nutriose HMC 6 according to the invention reduces intracellular water loss compared to a placebo lotion from day 0, at day 14 and at day 28. The aftershave lotion also reduces water loss at day 14 to the same extent as the reference product and at day 28 to a greater extent than the reference product.
[0481] Example 3: Clinical Study of Transepidermal Water Loss (TEWL) and Redness Induced by Sodium Lauryl Sulfate
[0482] The aim of this study was to determine the potential of hyperbranched dextrins (as reference substances by Roquette) during a clinical trial on volunteers. HM 06) on the redness produced by irritation of the inner forearm skin with a patch test using 10% SLS.
[0483] Volunteers and Products
[0484] The volunteers were the same as in the clinical study (shaving study) in Example 2, divided into the same groups, and used the same products (Table 6 in Example 2).
[0485] Material
[0486] Skin color was evaluated colorimetrically using a Minolta CM2600D TM spectrophotometer. Color measurements were made using the following parameters: standard 10° field of view, D65 illumination corresponding to daylight, measurement over an 8 mm2 area, using the L*a*b* color space, SCI method (including specular) to avoid the influence of surface conditions.
[0487] The vertical dimension L* represents the luminosity (or brightness), with values ranging from 0 (black) to 100 (white). The parameter a* determines a series of 600 levels on the red axis (+299 positive values) through gray (value 0) to green (-300 negative values). The parameter b* determines a series of 600 levels on the yellow axis (+299 positive values) through gray (value 0) to blue (-300 negative values). For this study, the parameter a* representing skin redness was determined.
[0488] Study plan
[0489] At the beginning of this study (day 0), the skin color and TEWL of the limited area on the two forearms of the volunteers were measured. Then, 10% SLS patches were placed on the two limited areas on the two forearms of each volunteer. The volunteers kept the patches for 20 hours and removed them 4 hours before the first day of measurement so that on the first day, skin color and TEWL were measured on the two forearms of all volunteers. After the first day of measurement, aftershave lotion was applied to the SLS patch treatment area on the right forearm immediately, and then skin color and TEWL were measured 5 minutes, 10 minutes and 30 minutes after this application. The left forearm was not treated.
[0490] Volunteers applied aftershave lotion to the SLS patch-treated area on their right forearm every night from day 1 to day 6. The left forearm received no treatment. On days 2, 3, 4, and 7, skin color and TEWL were measured on the areas treated with aftershave lotion and the control areas.
[0491] result
[0492] [Table 11]
[0493]
[0494] To compare the change in redness between different groups, calculate the change in redness between different measurement times, e.g. for the treated area of skin:
[0495] [Mathematical operation 1]
[0496] For all three groups, ΔTreatment((Day x)-Day 1)=(a* of treated area on Day x)-(a* of treated area on Day 1).
[0497] [Table 12]
[0498]
[0499] The table shows the change in redness over time between treated and untreated skin areas.
[0500] HM 06 hyperbranched dextrin significantly reduced SLS-induced redness as early as 10 minutes compared to placebo and control groups, and this reduction was maintained for up to 7 days. Skin redness was reduced by application of Nutriose HM 06 hyperbranched dextrin, demonstrating that this dextrin reduces skin inflammation caused by the 10% SLS patch.
[0501] Furthermore, this reduction in inflammation was faster than in the control group and therefore faster than the known anti-inflammatory bisabolol.
[0502] [Table 13]
[0503] Parameter a* Placebo group Reference group The present invention group Day 0 8.88 9.35 9.42 Day 1 19.12 23.95 24.27 Day 1 + 30min 18.78 23.17 19.21 Day 2 20.28 23.44 23.17 Day 3 19.37 20.74 21.22 Day 4 15.68 16.38 16.82 Day 7 15.73 14.55 14.24
[0504] The table shows the transepidermal water loss in the treated areas of the forearm.
[0505] [Table 14]
[0506] Parameter a* Placebo group Reference group The present invention group (Day 1 + 30min) - Day 1 -0.34 -0.775 -5.06 Day 2 - Day 1 1.16 -0.505 -1.095 Day 3 - Day 1 0.245 -3.205 -3.045 Day 4 - Day 1 -3.436 -7.565 -7.445 Day 7 - Day 1 -3.39 -9.4 -10.025
[0507] Table 14 shows the change in transepidermal water loss in the treated area of the forearm compared to Day 1.
[0508] HM 06 hyperbranched dextrin significantly reduced transepidermal water loss as early as 30 minutes after application, and then the water loss reduction value gradually increased during the treatment period of 2 to 7 days, reaching about 6.6 units greater than the placebo group (i.e., a difference of about 195%). Therefore, the hyperbranched dextrin helps maintain skin hydration by maintaining the skin barrier function.
[0509] Example 4: Cosmetic product formulation "Skin Care" comprising the hydrogenated highly branched dextrin as claimed herein Lover” Cream (SC-079-005)
[0510] [Table 15]
[0511]
[0512] Preparation method: at 45℃, HM 06 is added to water and mixed with a deflocculation centrifuge at 500 rpm until a clear solution is obtained. The ingredients of phase A2 are then mixed together in water under stirring at 500 to 1000 rpm. Phase A3 is then added to phase A1+A2 and stirred at 1500 rpm for 10 minutes. Separately, phase B is prepared by heating to 45°C, and then liquid phase B is emulsified in phase A1+A2+A3 for 15 minutes at 45°C with stirring at 2000 to 3000 rpm. Then cool to room temperature and add phases C and D. We finish by adding E and F pre-dissolved in a small amount of water. A blue emulsion with a Brookfield viscosity of 4500 to 5500 mPa.s (SP3 kinematic viscosity, 20 rpm, 20°C) is obtained.
[0513] After sun cream
[0514] [Table 16]
[0515]
[0516] Preparation protocol: Prepare phase A and phase B in two separate beakers at 70°C. Then emulsify phase B in phase A under high shear mixing for 10 minutes. Then cool to 20°C + / - 2°C. Add phase C under stirring followed by phase D. Finally, adjust the pH to 6. A white cream is obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle 4, 20 rpm).
[0517] After shave gel
[0518] [Table 17]
[0519]
[0520]
[0521] Preparation protocol: Isosorbide and Nutriose HMC 06 is premixed in the required amount of water in phase A and Beauté by Roquette DS112 starch is then dispersed therein at 80°C for 30 to 40 minutes. Phases B1 and B2 are then added successively and the pH is adjusted to 6. A translucent gel is obtained with a Brookfield viscosity of 3500 mPa.s + / - 700 (spindle 4, 20 rpm).
[0522] Soothing Oil-in-Water Emulsion
[0523] [Table 18]
[0524]
[0525] Preparation protocol: Add Nutriose HMC 06 to half the volume of water required for the formulation at 45°C, stirring at 500 rpm with a deflocculation centrifuge until a clear solution is obtained. Separately, mix the ingredients of phase A2 in half the volume of water required for the formulation under stirring at 500 to 1000 rpm. Then mix phase A1 with phase A2 and add phase A3 under stirring at 1500 rpm for 10 minutes. Separately, prepare phase B by heating to 45°C. Then emulsify phase B in phase A1+A2+A3 at 45°C under vigorous stirring at 2000 to 3000 rpm for 15 minutes. Cool it to 20°C+ / -2°C, then add phases C, D, E and F successively under stirring at 500 rpm, and adjust the pH to 5.3+ / -0.2. A blue emulsion with a Brookfield viscosity of 4500 to 5500 mPa.s (spindle No. 3, 20 rpm) was obtained.
[0526] Soothing Repair Hand Cream
[0527] [Table 19]
[0528]
[0529] Preparation protocol: Nutriose HMC 06 is added to the volume of water required for the formulation at 45°C, stirring with a deflocculation centrifuge at 500 rpm until a clear solution is obtained, then cooled to 20°C + / - 2°C. Beauté by Roquette DS 421 is then dispersed in phase A while stirring with a deflocculation centrifuge at 1000 rpm for approximately 10 minutes to hydrate the ingredient, which is confirmed by visual observation of its opalescence. Phase C is prepared separately. Phase C is slowly added to phases A+B at room temperature (20°C + / - 2°C) while stirring with a deflocculation centrifuge at 2000 to 3000 rpm, then kept stirring for 10 minutes. Finally, phase D is added while stirring at 1000 to 2000 rpm, then the pH is adjusted to 4.5-4.7. A yellow cream is obtained with a Brookfield viscosity of 8800 mPa.s (spindle No. 3, 20 rpm).
[0530] Soothing Cleansing Cream (TQ-027-001)
[0531] [Table 20]
[0532]
[0533]
[0534] Soothing Hair Conditioning Gel (HC-040-001)
[0535] [Table 21]
[0536]
[0537] Soothing Hair Conditioning Cream (HC-040-002)
[0538] [Table 22]
[0539]
Claims
1. A hyperbranched dextrin for topical use to prevent or treat at least one symptom selected from redness, heat, swelling and pain, characterized in that The hyperbranched dextrin comprises, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds: - up to 90% 1,4-glycosidic bonds, - At least 5% 1,6 glycosidic bonds.
2. The hyperbranched dextrin used according to claim 1, characterized in that It has: - at least 5% of 1,6-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-glycosidic bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15%, - up to 70% 1,4-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-bonds, preferably up to 60% and most preferably up to 50%, - at least 1% of 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.
3. The hyperbranched dextrin used according to claim 1, characterized in that The hyperbranched dextrin has: - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - 5% to 40% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
4. Hyperbranched dextrin for use according to one of claims 1 to 3, characterised in that The dextrin is a hyperbranched hydrogenated dextrin.
5. Hyperbranched dextrin for use according to one of claims 1 to 4, characterised in that The symptoms are located in at least one epithelial tissue selected from keratinized multilayer squamous epithelium, non-keratinized multilayer squamous epithelium, stratified columnar epithelium, and pseudostratified columnar epithelium with or without cilia.
6. Hyperbranched dextrin for use according to any one of claims 1 to 5 for preventing or treating symptoms of skin inflammation.
7. Hyperbranched dextrin for use according to any one of claims 1 to 5 for preventing or treating symptoms of mucosal inflammation.
8. The hyperbranched dextrin used according to claim 6, characterized in that The skin inflammation is induced by skin irritation, skin corrosion, endogenous skin inflammation or a combination of these causes.
9. The hyperbranched dextrin used according to claim 7, characterized in that Said inflammation of the mucous membrane is induced by ingredients contained in cosmetic, dermo-cosmetic, dermatological, pharmaceutical, medical, veterinary or household compositions or by mechanical aggression.
10. Hyperbranched dextrin for use according to any one of the preceding claims, characterized in that The at least one symptom, skin irritation, skin corrosion or skin inflammation is induced by at least one condition selected from the group consisting of: infectious agents, chemicals, ingredients contained in cosmetic, dermatological, pharmaceutical, veterinary, detergent or household compositions, mechanical insults, environmental factors, thermal insults, food and beverages.
11. Hyperbranched dextrin for use according to any one of the preceding claims, characterized in that The skin irritation is selected from cumulative irritant contact dermatitis, acute irritant contact dermatitis and phototoxic dermatitis.
12. Hyperbranched dextrin for use according to claim 6, wherein the skin inflammation is induced by a skin lesion involving an inflammatory process.
13. The hyperbranched dextrin used according to claim 12, characterized in that The lesions are selected from erythema, psoriasis, skin atopy, atopic dermatitis, immediate hypersensitivity type allergic reaction, delayed hypersensitivity type allergic reaction, inflammatory hyperpigmentation, immune skin disease, actinic elastosis, alopecia areata, vitiligo, systemic lupus erythematosus, pemphigus vulgaris, dystrophic epidermolysis and autoimmune white hair disease, erythema, etc.
14. Hyperbranched dextrin for use according to claim 7, wherein the mucosal inflammation is induced by a pathology involving an inflammatory process.
15. Use of hyperbranched dextrins for preventing, reducing or eliminating the irritating effects of ingredients contained in cosmetic, dermatological, medical, veterinary, detergent or household compositions, characterized in that The hyperbranched dextrin comprises, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds: - up to 90% 1,4-glycosidic bonds, - At least 5% 1,6 glycosidic bonds.
16. The use of the hyperbranched dextrin according to claim 15, characterized in that The hyperbranched dextrin has: - at least 5% of 1,6-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-glycosidic bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15%, - up to 70% 1,4-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-bonds, preferably up to 60% and most preferably up to 50%, - at least 1% of 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.
17. The use of the hyperbranched dextrin according to claim 15, characterized in that The hyperbranched dextrin has: - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - 5% to 40% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
18. Use of hyperbranched dextrins according to one of claims 15 to 17, characterized in that The ingredients are selected from surfactants, fragrances, solvents, preservatives, acids, alkalis and detergents.
19. A dermatological composition comprising hyperbranched dextrins, preferably hyperbranched hydrogenated dextrins, in a dermatologically acceptable medium, characterized in that The hyperbranched dextrin comprises, relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds: - up to 90% 1,4-glycosidic bonds, - At least 5% 1,6 glycosidic bonds.
20. The dermatological composition according to claim 19, characterized in that The hyperbranched dextrin has: - at least 5% of 1,6-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-glycosidic bonds, preferably at least 10%, more preferably at least 12%, and most preferably at least 15%, - up to 70% 1,4-glycosidic bonds relative to the sum of 1,2-, 1,3-, 1,4- and 1,6-bonds, preferably up to 60% and most preferably up to 50%, - at least 1% of 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%, - At least 1% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, preferably at least 5%, more preferably at least 10%, and most preferably at least 20%.
21. The dermatological composition according to claim 19, characterized in that The hyperbranched dextrin has: - 42% to 50% 1,4 glycosidic bonds relative to the sum of 1,2, 1,3, 1,4 and 1,6 bonds, - 5% to 40% 1,6 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,3 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds, - 1% to 20% 1,2 glycosidic bonds relative to the sum of 1,2 bonds, 1,3 bonds, 1,4 bonds and 1,6 bonds.
